预约演示
更新于：2026-05-07
Tenofovir
替诺福韦
更新于：2026-05-07
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 中国 (2008-06-18), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C9H16N5O5P |
InChIKeyPINIEAOMWQJGBW-FYZOBXCZSA-N |
CAS号206184-49-8 |
关联
278
项与 替诺福韦 相关的临床试验NCT07133776
A Multicenter, Single-Arm, Prospective Clinical Study to Evaluate the Efficacy and Safety of PD-1 Inhibitor Combined With Tenofovir, Chidamide, and Lenalidomide in the Treatment of EBV-Associated Diseases
Currently, treatment options for Epstein-Barr virus (EBV) infection are limited, with unsatisfactory efficacy and no established standard therapy. Therefore, our center is conducting a prospective, multicenter, single-arm clinical trial to evaluate the efficacy and safety of PD-1 inhibitor in combination with tenofovir, chidamide, and lenalidomide in patients with EBV infectious diseases, aiming to provide a more effective and safer therapeutic option for EBV infectious diseases.
开始日期2025-09-01 |
申办/合作机构 |
NCT07133763
A Multicenter, Single-Arm, Prospective Study to Evaluate the Efficacy and Safety of PD-1 Inhibitor Combined With Tenofovir, Chidamide, and Lenalidomide in the Treatment of Relapsed or Refractory EBV-Associated Lymphoproliferative Disorders.
This study is a prospective, multicenter, single-arm clinical trial designed to evaluate the efficacy and safety of PD-1 inhibitor combined with tenofovir, chidamide, and lenalidomide in the treatment of relapsed or refractory Epstein-Barr virus (EBV)-associated lymphoproliferative disorders (LPDs). The primary endpoint is the overall response rate (ORR) at 3 months, including complete response (CR) and partial response (PR). Secondary endpoints include overall survival (OS), progression-free survival (PFS), as well as safety and tolerability assessments. Eligible patients must have histologically confirmed EBV-positive B-cell or T/NK-cell LPDs with measurable lesions. This combination regimen targets multiple mechanisms, including inhibition of EBV replication, activation of the immune system, and enhancement of antitumor effects, aiming to provide an innovative therapeutic strategy for this challenging disease.
开始日期2025-09-01 |
申办/合作机构 |
NCT07095855
A Multicenter, Randomized, Double-Blind, Placebo-Controlled and Open-Label Extension Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R (Canocapavir) in Combination With Nucleos(t)Ide Analog(NAs) Compared With NAs Monotherapy in Patients With Chronic Hepatitis B Who Have Received NAs Monotherapy for at Least 12 Months
This study is divided into two parts. Part A is a multicenter, randomized, double-blind, placebo controlled phase Ill clinical trial, designed to evaluate the efficacy and safety of ZM-H1505R in combination with NAs versus NAs monotherapy with HBV DNA ≥ 50 IU/mL and are HBeAg positive who have received NAs monotherapy for at least 12months.Part B is an open-label extension and follow-up period designed to evaluate the long-term safety and efficacy of ZM-H1505R in combination with NAs.
开始日期2025-08-01 |
申办/合作机构 |
100 项与 替诺福韦 相关的临床结果
登录后查看更多信息
100 项与 替诺福韦 相关的转化医学
登录后查看更多信息
100 项与 替诺福韦 相关的专利（医药）
登录后查看更多信息
4,829
项与 替诺福韦 相关的文献（医药）2026-06-01·TISSUE & CELL
Protective effects of linagliptin and tenofovir disoproxil fumarate against APAP-induced acute liver injury: A biochemical, histological, and computational study
Article
作者: Jamil, Salim ; Al-Emam, Ahmed ; Alsaleem, Mansour Abdulaziz ; Hassan, Hesham M ; Yamin, Mahnoor ; Ali, Muhammad ; Akhtar, Bushra ; Mehreen, Arifa
Hepatic injuries are one of the leading threats to public health which can further lead to liver diseases such as liver fibrosis and cirrhosis. An overdose of certain chemicals and drugs can cause hepatotoxicity, which leads to drug-induced liver injury. Linagliptin is an effective drug in treating type 2 diabetes, as it has been shown to reduce oxidative stress. Tenofovir (an antiretroviral) is the first-line treatment for hepatitis B and AIDS; it inhibited the production of reactive oxygen species (ROS) and reduced inflammation. The present research was conducted to assess protective effect of two FDA-approved repurposed (anti-diabetic and antiretroviral) drugs against APAP-induced acute liver injury in mouse models. A multi-model approach was applied by integrating in vivo, in vitro, and silico techniques with histopathological analysis. APAP injection enhanced ALT, AST, ALP, and bilirubin levels. In vivo analysis exhibited ameliorated liver injury with Lina and TDF, as evidenced by significantly lowered liver injury markers. Combination therapy normalized insulin levels, indicating improved glycemic control. Both drugs increased TAC and decreased levels of TOS and MDA. In Silico studies revealed a strong interaction between Lina and TDF with pro-inflammatory receptors, including JNK, TNF-α, and IL-1. Histopathological analysis further proved the reversal of acute liver injury. Together, Lina and TDF acted as multi-target anti-liver injury drugs, indicating their potential as a promising hepato-therapeutic repurposed drug.
2026-05-01·JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
Brief Report: Hepatitis B Vaccination Histories in Persons With HIV Needing Revaccination
Article
作者: Kosgei, Josphat ; Kang, Minhee ; Ngan, Ta Thi Dieu ; Chakalisa, Unoda ; Cardoso, Sandra W. ; Sherman, Kenneth E. ; Marks, Kristen M. ; Avihingsanon, Anchalee ; Caruso, Stephanie ; Umbleja, Triin ; Vigil, Karen J.
Introduction::
Past studies of hepatitis B vaccines in people with HIV (PWH) have shown mixed results about improving responses with increases in dose or dose frequency, leading to inconsistent guidelines and practice. We examined vaccine series completion and revaccinations in PWH lacking a seroprotective response.
Methods::
Hepatitis B vaccination histories were evaluated as a retrospective study in 561 participants of A5379 trial (NCT04193189). Individuals in 41 sites in Africa, Asia, South America, and the United States qualified for the trial with antibody titers below the seroprotective level (<10 mIU/mL) despite past hepatitis B vaccinations. The primary measure of interest was the number of vaccines in the past vaccination records.
Results::
Of the 1098 trial candidates, 561 (51%) did not have seroprotective titers at the time of screening and enrolled in A5379. Median age at the time of screening was 46 years (18–70 years), which varied across the regions: the lowest in Africa and the highest in the United States. The number of past hepatitis B vaccines varied widely across and within geographic regions. Twenty-four percent of the participants received ≥4 doses, up to 12, yet did not have seroprotective antibody titers.
Conclusions::
Regardless of past vaccine records, antibody titers should be checked in PWH for revaccination needs. The recently approved long-acting and injectable antiretroviral treatment (ART) lacks protective effect against HBV, unlike tenofovir-based ART. As the long-acting ART becomes more widely used, we recommend reassessing serologies and offering the recommended CpG-adjuvanted vaccine series with promising response durability to individuals without seroprotection.
2026-05-01·Current Opinion in HIV and AIDS
Use of dual ART in individuals with different HBV serological patterns
Review
作者: Bhagani, Sanjay ; Swaine, Thomas
Purpose of review:
Two-drug regimens (2DR) for antiretroviral therapy are increasingly being recommended for people living with HIV to reduce pill burden and reduce short and long-term toxicity. The exclusion of tenofovir and lamivudine or emtricitabine has implications for acquisition of and reactivation of hepatitis B.
Recent findings:
A number of case-series, cohort studies and randomized-controlled trials of 2Drs have reported on the risk of HBV acquisition and HBV-reactivation (HBVr). The risk of HBVr appears negligible in those switching to 2DRs containing lamivudine, and overall low (~1%) in those switching to tenofovir and lamivudine/emtricitabine-free therapy. Even remote HBsAg positivity is associated with a significant risk of HBVr.
Summary:
For people with HIV switching to 2DRs careful attention needs to be paid to preswitch HBV serological patterns. For those without previous exposure, and absence of HBsAb, vaccination is important. The risk of HBVr of switching to lamivudine-containing regimens is negligible, and low without tenofovir and lamivudine/emtricitabine. Careful monitoring and preswitch counselling is advised.
643
项与 替诺福韦 相关的新闻（医药）2026-05-06
·翰森制药
2026年5月6日，翰森制药集团有限公司（“翰森制药”，03692.HK）宣布，在近日于土耳其召开的亚太肝病研究学会（APASL）年会上，中国首个原研口服抗乙型肝炎病毒（HBV）药物恒沐®（艾米替诺福韦，TMF）有8项研究入选，其中包括2项口头报告（Oral presentation）和6项电子壁报（E-poster），涵盖联合干扰素、低病毒血症（LLV）管理、肝细胞癌（HCC）术后、老年人群、肝硬化及血脂安全性等多个研究方向，全方位展示了恒沐®在真实世界中的疗效与安全性[1-8]。
两项口头报告分别聚焦于“联合聚乙二醇干扰素α-2b优化HBsAg清除”及“低病毒血症（LLV）的风险因素与优化策略”，为临床提供了极具价值的新方案。
摘要编号：1619
研究标题：Safety and Effectiveness of Peginterferon Alfa 2b Combined with Tenofovir Amibufenamide in Patients with Chronic Hepatitis B[1]
报告形式：口头报告
作者：曾庆磊（郑州大学第一附属医院）等
● 研究方法
研究回顾性纳入2022年1月至2025年5月期间来自中国河南三家医院接受TMF（25mg/天）和Peg-IFN α-2b（180μg/周）治疗的患者。分为两组：一组从核苷（酸）类似物（NUC）单药治疗转换为TMF联合Peg-IFN α-2b治疗（转换联合组）；另一组接受TMF联合Peg-IFN α-2b作为初始治疗（初治联合组）。主要终点是治疗48周时的乙型肝炎表面抗原（HBsAg）清除率。
●研究结果
研究结果显示，共纳入180例患者，其中转换联合组120例，初治联合组60例。转换组中NUC单药治疗的治疗时间为67.45±35.36个月。治疗48周时，转换联合组的HBsAg清除率达44.16%，显著高于初治联合组的28.33%（P=0.040）。转换联合组的HBeAg清除率达76.67%，也显著优于初治联合组（42.86%，P=0.026）。两组HBV DNA不可测率均超过96%，病毒抑制效果优异。治疗期间常见不良反应为丙氨酸氨基转移酶（ALT）升高、白细胞及血小板减少等，均在可控范围内，未发生严重不良事件。
● 研究结论
研究表明，先使用NUC治疗，再联合恒沐®与聚乙二醇干扰素α-2b，相较于直接联合治疗，能显著提高HBsAg清除率。这为追求临床治愈的慢性乙肝(CHB)患者提供了一条更优路径，具有重要的临床推广价值。
摘要编号：2711
研究标题：Related Factors for Low Level Viremia and the Comparative Efficacy of Management Strategies in Treatment Naïve Chronic Hepatitis B Patients Receiving Entecavir or Tenofovir Amibufenamide: A Real World Study[2]
报告形式：口头报告
作者：潘修成（徐州医科大学附属医院）等
●研究方法
研究共纳入743例初治CHB患者，其中467例接受恩替卡韦（ETV）治疗，276例接受TMF治疗。经过48周随访后，患者被分为完全病毒学应答（CVR）组或低病毒血症（LLV）组。随后，LLV患者接受了不同的管理策略：
ETV单药治疗后出现LLV的患者（ETV-LLV）接受三种干预措施之一：继续ETV单药治疗、转换为丙酚替诺福韦/艾米替诺福韦（TAF/TMF）单药治疗、或加用TAF/TMF。
TMF单药治疗后出现LLV的患者（TMF-LLV）接受继续TMF单药治疗或加用ETV。
●研究结果
研究结果显示，经倾向性评分匹配后，TMF组48周完全病毒学应答率显著更高（76.80% vs. 62.50%，P<0.001）。多因素分析显示：高基线HBV DNA、HBsAg、HBeAg（高COI）、肝硬化、脂肪肝是LLV的独立危险因素；初始使用TMF是LLV的显著保护因素（aOR=0.236，P<0.001）。对于ETV经治后出现LLV的患者，加用TAF/TMF组的完全病毒学应答率（72.3%）显著高于继续ETV单药组（40.4%，P=0.003），且HBV DNA和HBsAg降幅更大。而对于TMF经治后出现LLV的患者，加用ETV未带来显著额外获益。
● 研究结论
该研究首次在大样本真实世界中明确了恒沐®较恩替卡韦在降低LLV风险方面的优势，并首次提出：对于ETV治疗后出现LLV的患者，“加用恒沐®或TAF”是更优的挽救策略；而对于恒沐®治疗后仍为LLV者，应探索其他联合方案而非简单加用ETV。这一发现对临床个体化治疗具有重要指导意义。
除口头报告以外，APASL 2026 还发布了恒沐®治疗HBV相关肝癌术后患者96周数据，显示恒沐®治疗组有85%实现HBV DNA不可测，ALT复常率达92.5%，且血脂谱优于ETV组[3]；另一项关于血脂安全性的研究显示，恒沐®治疗48周期间对脂质代谢无显著影响[4]；一些真实世界研究证实了恒沐®在老年CHB和（或）肝硬化人群中同样安全有效[5,6]。
上述研究数据的发布，进一步夯实了恒沐®在CHB全线治疗中的循证基础。恒沐®将继续在更广泛人群、更长疗程及更多联合方案研究中持续探索，助力更多CHB患者实现临床治愈目标，为全球乙型肝炎防治贡献中国力量。
参考文献：
1.Qinglei Zeng,et al.Safety and Effectiveness of Peginterferon Alfa 2b Combined with Tenofovir Amibufenamide in Patients with Chronic Hepatitis B.APASL 2026.Abstract No.1619
2.Xiucheng Pan,et al.Related Factors for Low Level Viremia and the Comparative Efficacy of Management Strategies in Treatment Naïve Chronic Hepatitis B Patients Receiving Entecavir or Tenofovir Amibufenamide A Real World Study. APASL 2026.Abstract No.2711.
3.Qinglei Zeng,et al.Effectiveness and Safety of 96 Week Tenofovir Amibufenamide in Patients with Hepatitis B Virus Related Hepatocellular Carcinoma A Retrospective Real World Study. APASL 2026.Abstract No.1793.
4.Jingjing Wang,et al.Real world impact of 48 week tenofovir amibufenamide therapy on lipid profiles in chronic hepatitis B. APASL 2026.Abstract No.2658.
5.Gao Chen.Efficacy and Safety of Tenofovir Amibufenamide in the Treatment of Elderly Patients with Chronic Hepatitis B and Liver Cirrhosis. APASL 2026.Abstract No.2060.
6.Gao Chen.Real World Study of Tenofovir Amibufenamide in the Treatment of Hepatitis B Related Liver Cirrhosis. APASL 2026.Abstract No.2061.
7.Jiarui Zheng,et al.Efficacy and safety of tenofovir amibufenamide in patients with chronic hepatitis B An observational study. APASL 2026.Abstract No.1347.
8.Gao Chen.Cost Effectiveness Evaluation of Elmetenovir in the Treatment of Chronic Hepatitis B. APASL 2026.Abstract No.2055.
关于翰森制药
翰森制药是中国领先的创新驱动型制药企业，下属豪森药业、常州恒邦药业、翰森生物医药等子公司，以「持续创新，提高人类生命质量」为使命，重点关注抗肿瘤、抗感染、中枢神经系统、代谢及自身免疫等重大疾病治疗领域。截至目前，公司在中国产生销售收入的创新药共7款，形成了丰富的产品管线。翰森制药连续多年位居全球制药企业百强、中国医药研发产品线最佳工业企业前3强，是国家重点高新技术企业、国家技术创新示范企业。翰森制药于2019年6月在香港联交所挂牌上市（股票代码：03692.HK）。
免责声明
本文仅供医疗卫生专业人士参阅，非广告用途。翰森制药不推荐任何未获批药品使用和/或未获批适应症用药，亦不对任何药品和/或适应症作推荐。本文中涉及的信息仅供参考，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。如需了解公司任何产品、医疗或疾病的相关信息，请务必咨询医疗卫生专业人士。
前瞻性说明
本新闻稿旨在提供关于翰森制药集团有限公司及其附属公司（包括其子公司，统称为“翰森制药”）的信息。它不构成对翰森制药或任何投资建议的信息披露。本新闻稿包含的信息可能包括与翰森制药业务和产品前景、计划、信念、预期和策略相关的前瞻性声明。这些声明是基于推测性假设的预测，并不保证未来的表现。它们受到诸如科学、商业、政治、经济、财务、法律因素以及竞争环境和社会条件等风险和不确定性的影响，这些因素很多都是翰森制药无法控制且难以预测的，因此实际结果可能与此处所述有显著差异，且过去的证券价格趋势不应作为未来行情的指导。因此，投资者在使用这些信息进行投资决策时应谨慎行事。“致力于”“预期”“相信”“预测”“意图”“预计”“可能”“将”“应该”“计划”“继续”“目标”“考虑”“估计”“指导”“潜在”“追求”以及于任何未来计划、行动或事件的讨论中使用的类似词语和术语，均表示前瞻性声明。翰森制药不承诺或保证前瞻性信息的准确性、及时性或完整性，并且不承担更新或修订这些前瞻性声明的义务。无论是翰森制药还是其任何董事、员工或代理人，均不对任何证明不准确或无法实现的前瞻性声明负责，也不对因依赖本新闻稿中提供的信息而产生的任何损失或损害负责，包括但不限于直接、偶然、间接或惩罚性的损害。
2026-05-06
5月6日，广生堂涨1.45%，成交额8.57亿元，换手率5.28%，总市值189.53亿元。异动分析创新药+仿制药一致性评价+辅助生殖+基因测序+肝炎概念1、拥有抗乙肝病毒新药替诺福韦(福甘定),止血止痛药三升金丹胶囊取得新药证书及药品批准文号;17年9月,新型肝癌靶向新药 GST-HO161项目已经确定临床前候选化合物(PCC)18年3月,与药明康德合作研发治愈乙肝、脂肪肝新药、肝癌新药等四个一类创新药,目前肝癌与脂肪肝新药已取得药监局临床试验批件;19年2月,∞STHG151非酒精性脂肪肝病及肝纤维化可逆转全球创新药临床申请获得国家药品监督管理局受理拥有抗乙肝病毒新药替诺福韦(福甘定)。2、公司两大主力产品恩替卡韦胶囊、富马酸替诺福韦二吡呋酯胶囊均已通过仿制药一致性评价；阿德福韦酯片已提交一致性评价申请，目前正根据CDE的补充研究通知开展药学补充研究；拉米夫定片已提交了仿制药一致性评价申请。3、全资子公司广生堂辅助生殖海外有限公司主营从事生殖技术的研发、转让、咨询、服务等。4、公司联营公司福建博奥医学检验所有限公司可提供基因检测服务，其承建的 “国家（福建）基因检测技术应用示范中心”，是国家发改委公布的全国首批 27 个基因检测技术应用示范中心之一，也是福建省首个基因检测技术应用示范中心。5、广生堂主要销售抗乙肝病毒药物和保肝护肝药物等化药产品。广生堂（母公司）拥有茵白肝炎胶囊、茵白肝炎颗粒、灵芝胶囊、降压茶、复方丹参片等中成药药品注册批件，除灵芝胶囊有极少量销售外，其余目前暂未销售；控股子公司中兴药业有销售益肝灵片、复方益肝灵片、参芪健胃颗粒、参梅养胃颗粒（无蔗糖）、参梅养胃颗粒、顺气化痰片、顺气化痰颗粒等中成药产品，但销售占比很小。(免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断)资金分析今日主力净流入-4509.62万，占比0.05%，行业排名152/158，连续2日被主力资金减仓；所属行业主力净流入-7.08亿，连续3日被主力资金减仓。区间今日近3日近5日近10日近20日主力净流入-4509.62万-5100.65万-1.80亿-2.63亿-7.37亿主力持仓主力没有控盘，筹码分布非常分散，主力成交额3.98亿，占总成交额的9.05%。技术面：筹码平均交易成本为116.03元该股筹码平均交易成本为116.03元，近期筹码减仓，但减仓程度减缓；目前股价靠近压力位122.00，谨防压力位处回调，若突破压力位则可能会开启一波上涨行情。公司简介资料显示，福建广生堂药业股份有限公司位于福建省福州市闽侯县福州高新区乌龙江中大道7号海西高新技术产业园创新园二期16号楼，成立日期2001年6月28日，上市日期2015年4月22日，公司主营业务涉及核苷类抗乙肝病毒药物的研发、生产与销售。主营业务收入构成为：医药制造98.18%，其他1.82%。广生堂所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：创新药、新冠药物、抗癌药物、肿瘤治疗、生物医药等。截至3月31日，广生堂股东户数3.49万，较上期增加1.60%；人均流通股3913股，较上期减少1.58%。2026年1月-3月，广生堂实现营业收入9844.02万元，同比增长0.85%；归母净利润-2592.43万元，同比增长9.00%。分红方面，广生堂A股上市后累计派现8464.85万元。近三年，累计派现0.00元。机构持仓方面，截止2026年3月31日，广生堂十大流通股东中，广发科技先锋混合（008903）位居第五大流通股东，持股252.10万股，为新进股东。广发双擎升级混合A（005911）位居第七大流通股东，持股215.71万股，为新进股东。香港中央结算有限公司退出十大流通股东之列。声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系biz@staff.sina.com.cn。
2026-05-06
Clinical Infectious Diseases Volume 82 Issue 1
临床传染病学 82卷1期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时代的传染病学技艺）
1
Peasants' Revolt, 1381
1381年农民起义
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page i, https://doi.org/10.1093/cid/ciaf692
In the Literature（文献概览）
2
In the Literature
文献概览
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages ii–iii, https://doi.org/10.1093/cid/ciaf631
State-of-the-Art Review（最新技术综述）
3
State-of-the-Art Review: Diagnosis and Management of Acute and Chronic Bacterial Prostatitis
最新技术综述：急性和慢性细菌性前列腺炎的诊断与治疗
Prathit A Kulkarni and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 1–13, https://doi.org/10.1093/cid/ciaf483
Clinical Dilemmas in Infectious Diseases（传染病临床难题）
4
“Insisting on Treatment”
“坚持治疗”
Kevin Andrew Smith and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 14–18, https://doi.org/10.1093/cid/ciaf282
Voices of ID（传染病之声）
5
Martin Arrowsmith and Me
马丁·阿罗史密斯与我
Janet R Gilsdorf
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 19–20, https://doi.org/10.1093/cid/ciaf277
Invited Commentary（特邀述评）
6
The 2025 Centers for Disease Control and Prevention Nonoccupational HIV Postexposure Prophylaxis Guidelines: Updated Regimens and Remaining Questions
2025年美国疾病控制与预防中心非职业性艾滋病毒暴露后预防指南：更新方案及遗留问题
Lao-Tzu Allan-Blitz and Kenneth H Mayer
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 21–24, https://doi.org/10.1093/cid/ciaf567
Antimicrobial Resistance and Stewardship（抗菌药物耐药性与管控）
7
Modeling the Impact and Cost of a Culture-Dependent Molecular Test for Antimicrobial Resistance in Resource-Limited Settings
资源有限环境下，基于培养的分子检测法对抗菌药物耐药性的影响和成本建模
Joshua M Chevalier and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 25–32, https://doi.org/10.1093/cid/ciaf236
8
The Xpert MTB/RIF Cycle Threshold Value Predicts Mycobacterium tuberculosis Transmission to Close Contacts in a Brazilian Prospective Multicenter Cohort
巴西一项前瞻性多中心队列研究中Xpert MTB/RIF循环阈值可预测结核分枝杆菌在密切接触者中的传播
Leandro S Garcia and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 33–41, https://doi.org/10.1093/cid/ciad794
9
Beyond Diagnosis: Xpert Cycle Threshold Values as Predictors of Tuberculosis Transmission
超越诊断：Xpert循环阈值作为结核病传播的预测指标
Lauren Linde and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 42–43, https://doi.org/10.1093/cid/ciad791
10
First Report of Treatment-Emergent Resistance to Cefepime-Zidebactam in Pseudomonas aeruginosa
铜绿假单胞菌在头孢吡肟-齐德巴坦治疗中出现耐药性的首例报告
Ava J Dorazio and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 44–48, https://doi.org/10.1093/cid/ciaf638
Clinical Practice and Policy（临床实践与政策）
11
Sputum and Tongue Swab Molecular Testing for the In-Home Diagnosis of Tuberculosis in Unselected Household Contacts: A Cost and Cost-Effectiveness Analysis
痰液和舌拭子分子检测用于未筛选家庭接触者结核病居家诊断的成本及成本效益分析
Charl Bezuidenhout and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 49–57, https://doi.org/10.1093/cid/ciaf389
12
You’ve Got a Friend in Me: Curbside Questions Infectious Diseases Clinicians Ask Infectious Diseases Pharmacists
我是你的朋友：传染病临床医生向传染病药剂师咨询的即兴问题
Matthew R Davis and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 58–61, https://doi.org/10.1093/cid/ciaf250
13
Home Testing for Contagious Illness: Historical Context and Modern Caveats
传染性疾病居家检测：历史背景与现代注意事项
Abigail Zuger
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 62–66, https://doi.org/10.1093/cid/ciaf623
Fungal Infections（真菌感染）
14
Evaluating the Use of Lower Dose Flucytosine for the Treatment of Cryptococcal Meningitis: A Clinical Trial
评估低剂量氟胞嘧啶治疗隐球菌性脑膜炎的临床试验
Morris K Rutakingirwa and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 67–74, https://doi.org/10.1093/cid/ciaf432
15
Association Between Duration of Candidemia and Clinical and Healthcare Resource Utilization Outcomes Among Hospitalized Adult Patients With Candidemia Who Received Empiric Treatment With an Echinocandin Across United States Hospitals
美国各医院中接受棘白菌素经验性治疗的念珠菌血症成年住院患者中，念珠菌血症持续时间与临床和医疗资源利用结局之间的关联
Thomas P Lodise and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 75–85, https://doi.org/10.1093/cid/ciaf472
16
Aspergillosis-Attributable Mortality in the United States: Analysis of Death Certificate Data
美国隐球菌病导致的死亡率分析：基于死亡证明数据
Thomas J Walsh and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 86–92, https://doi.org/10.1093/cid/ciaf653
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
17
Outcomes of Critical Illness in People With Advanced HIV Disease: 30 Years of Binational Data
晚期艾滋病患者危重症结局：30年的双国数据
Bryan Tan and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 93–99, https://doi.org/10.1093/cid/ciaf362
18
Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults With HIV-1: ACTG A5357
长效卡博特韦和VRC07-523LS用于HIV-1感染成人病毒抑制的2期试验：ACTG A5357
Babafemi O Taiwo and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 100–108, https://doi.org/10.1093/cid/ciaf375
19
Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine in a National Cohort of People With HIV-1: First Results From the ANRS-MIE CARLAPOP Study
全国HIV-1感染者队列中长效卡博特韦和利匹韦林的治疗药物监测：ANRS-MIE CARLAPOP研究的首批结果
Nadège Néant and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 109–118, https://doi.org/10.1093/cid/ciaf385
20
Is Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine of Clinical Utility?
长效卡博特韦和利匹韦林的治疗药物监测是否具有临床实用性？
Catia Marzolini
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 119–121, https://doi.org/10.1093/cid/ciaf386
21
Efficacy and Safety of Dual Therapy With Dolutegravir/Lamivudine in Treatment-naive Persons With CD4 Counts <200/mm3: 48-Week Results of the DOLCE Study
多替拉韦/拉米夫定双药治疗在CD4计数<200/mm³的初治患者中的疗效和安全性：DOLCE研究48周结果
Maria Ines Figueroa and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 122–131, https://doi.org/10.1093/cid/ciaf415
22
DOLCE: Sweet Success for Dolutegravir/Lamivudine?
DOLCE研究：多替拉韦/拉米夫定双药治疗是否取得完美成功？
Laura J Waters
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 132–133, https://doi.org/10.1093/cid/ciaf416
Infection Control and Hospital Epidemiology（感染控制与医院流行病学）
23
Real-Time Genomic Surveillance for Enhanced Healthcare Outbreak Detection and Control: Clinical and Economic Impact
实时基因组监测用于加强医疗保健机构疫情检测与控制：临床与经济影响
Alexander J Sundermann and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 134–141, https://doi.org/10.1093/cid/ciaf216
24
Patient Perspectives Regarding Different Contact Precaution Policies for Methicillin-resistant Staphylococcus aureus Across Two Hospitals: Patients Are in Favor of Contact Precautions
两家医院患者对耐甲氧西林金黄色葡萄球菌不同接触预防政策的态度：患者支持接触预防措施
Nicholas F Angelino and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 142–144, https://doi.org/10.1093/cid/ciaf330
Photo Quiz（影像问答）
25
The Clue That Wriggled into View
蜿蜒入目的线索
Nitin Gupta and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 145–147, https://doi.org/10.1093/cid/ciaf427
Infection Control and Hospital Epidemiology（感染控制与医院流行病学）
26
Comparing Generative Artificial Intelligence vs Experts for Detection of Catheter-Associated Urinary Tract Infection
比较生成式人工智能与专家在导管相关尿路感染检测中的应用
Shatha Alshanqeeti and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 148–150, https://doi.org/10.1093/cid/ciaf486
Sexually Transmitted Infections（性传播感染）
27
Viability of Chlamydia trachomatis in Different Anatomical Sites—a Systematic Review and Meta-analysis
不同解剖部位沙眼衣原体的存活能力——系统综述和荟萃分析
Arthur Wong and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 151–158, https://doi.org/10.1093/cid/ciae401
Photo Quiz（影像问答）
28
A 46-Year-Old With Persistent Altered Mental Status and Respiratory Failure
一例46岁患者持续出现意识状态改变伴呼吸衰竭
Ann F Yang and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 159–161, https://doi.org/10.1093/cid/ciaf439
Sexually Transmitted Infections（性传播感染）
29
Mpox in People With HIV: Predictors of Diagnosis, Outcomes, and Vaccine Effectiveness in a Multisite Cohort
HIV感染者中的猴痘：多站点队列中诊断、预后和疫苗有效性的预测因素
Michalina Montaño and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 162–172, https://doi.org/10.1093/cid/ciae464
30
Development and Evaluation of a Novel Algorithm to Identify Doxycycline Postexposure Prophylaxis Users at a Large Healthcare System in the Bronx, New York
开发和评估一种新型算法，用于识别纽约布朗克斯区一家大型医疗系统中多西环素暴露后预防用药者
Caroline E Mullis and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 173–176, https://doi.org/10.1093/cid/ciaf109
31
Evidence-Informed Provision of Doxycycline Postexposure Prophylaxis for Prevention of Bacterial Sexually Transmitted Infections
为预防细菌性性传播感染提供基于证据的多西环素暴露后预防用药
Julia C Dombrowski and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 177–184, https://doi.org/10.1093/cid/ciae527
Bacterial Infections（细菌性感染）
32
Long-term Mortality Trends Among Individuals With Tuberculosis: A Retrospective Cohort Study of Individuals Diagnosed With Tuberculosis in Brazil
巴西结核病患者的长期死亡率趋势：一项针对巴西结核病诊断患者的回顾性队列研究
Sun Kim and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e1–e8, https://doi.org/10.1093/cid/ciaf206
33
Clinical and Microbiological Characteristics of Meningococcal Eye Infections: Retrospective National Surveillance in England, 2010–2022
脑膜炎球菌眼部感染的临床和微生物学特征：2010 - 2022年英格兰全国回顾性监测
Stephen A Clark and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e9–e16, https://doi.org/10.1093/cid/ciaf274
34
Does Piperacillin-Tazobactam Increase Mortality Risk Compared With Cefepime? Collider Bias and the Importance of Assumptions in Instrumental Variable Analyses
与头孢吡肟相比，哌拉西林-他唑巴坦是否会增加死亡率风险？工具变量分析中的混杂偏倚和假设的重要性
Fergus Hamilton and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e17–e23, https://doi.org/10.1093/cid/ciaf317
COVID-19 / SARS COV-2（新冠肺炎/严重急性呼吸综合征冠状病毒2型）
35
Efficacy and Safety of Obeldesivir in High-Risk Nonhospitalized Patients With COVID-19 (BIRCH): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
奥贝德西韦在高危非住院COVID-19患者（BIRCH研究）中的疗效和安全性：一项3期、随机、双盲、安慰剂对照研究
Anca Streinu-Cercel and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e24–e32, https://doi.org/10.1093/cid/ciaf406
36
Retreatment With Nirmatrelvir/Ritonavir Following Return of COVID-19 Symptoms and SARS-CoV-2 Positivity
COVID-19症状复发且SARS-CoV-2检测呈阳性后使用奈玛特韦/利托那韦重新治疗
Wuyan Zhang and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e33–e40, https://doi.org/10.1093/cid/ciaf548
Emerging Infections(新兴感染)
37
“I Didn’t Know Him Before the Pandemic… Now He's on My Speed Dial”: Strengthening Collaboration Between Infectious Diseases Physicians and State and Local Public Health for Future Public Health Emergencies
“疫情前我并不认识他……现在他已是我的快速拨号对象”：加强传染病医生与州和地方公共卫生部门在未来突发公共卫生事件中的合作
Diana Valencia and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e41–e46, https://doi.org/10.1093/cid/ciaf179
38
Identification of and Response to Influenza A(H5) in Off-the-Shelf Raw Milk—Santa Clara County, California, November–December 2024
2024年11 - 12月加利福尼亚州圣克拉拉县在现成生牛奶中检出甲型流感（H5）病毒及应对措施
Alessandra Løchen and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e47–e48, https://doi.org/10.1093/cid/ciaf420
39
The Indispensable Value of Small-Molecule Antivirals in Epidemic and Pandemic Preparedness
小分子抗病毒药物在流行病和大流行病防范中的不可或缺价值
Ruxandra Draghia-Akli and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e49–e55, https://doi.org/10.1093/cid/ciaf476
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
40
Increasing HIV Testing During Gonorrhea and Chlamydia Evaluations in Urgent Care and Emergency Departments: A Large Health System Initiative
在紧急护理和急诊科进行淋病和衣原体检测时增加HIV检测：一项大型医疗系统倡议
Allan M Seibert and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e56–e67, https://doi.org/10.1093/cid/ciaf434
41
Clinical Predictors and Incidence of Kaposi Sarcoma Among Males With HIV in the Treat-All Era in the United States and Canada
美国和加拿大“全员治疗”时代男性HIV感染者卡波西肉瘤的临床预测因素和发病率
Sally B Coburn and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e68–e77, https://doi.org/10.1093/cid/ciaf446
42
Integrase Strand Transfer Inhibitors for Treatment-experienced Young Adults With Perinatal HIV in the US: Immunologic, Virologic, and Anthropometric Outcomes
美国接受过治疗的围产期感染HIV的年轻成人使用整合酶链转移抑制剂的免疫学、病毒学和人体测量学结果
Kunjal Patel and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e78–e88, https://doi.org/10.1093/cid/ciaf538
43
Win Ratio Aligns With and Enhances Interpretation of REPRIEVE's Primary Findings
Win比值与REPRIEVE研究的主要发现一致并增强了其解释性
Emma Davies Smith and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e89–e92, https://doi.org/10.1093/cid/ciaf477
44
The Critical Importance of Clinical Use Case to Inform Point-of-Care Technology Development: A Case Study of HIV Nucleic Acid Assays in the United States
临床应用案例对于指导即时检测技术开发的重要性：以美国HIV核酸检测为例
Yukari C Manabe and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e93–e99, https://doi.org/10.1093/cid/ciaf510
Mycobacterial Infections（分枝杆菌感染）
45
Body Mass Index and Incident Tuberculosis in Close Tuberculosis Contacts
结核密切接触者中体重指数与新发结核病的关系
María B Arriaga and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e100–e109, https://doi.org/10.1093/cid/ciaf475
46
The Role of Youths in Within-Household Tuberculosis Transmission: A Household Contact Cohort Study
青年在家庭内结核病传播中的作用：一项家庭接触队列研究
Meredith B Brooks and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e110–e118, https://doi.org/10.1093/cid/ciaf490
47
Cost-effectiveness of Targeted Next-Generation Sequencing for Tuberculosis Drug-resistance Testing as an Alternative to the Standard of Care in South Africa
南非以靶向下一代测序作为结核病耐药检测标准护理方案的替代方案的成本效益分析
Alexandra de Nooy and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e119–e125, https://doi.org/10.1093/cid/ciaf495
48
Xpert MTB/RIF Cycle Threshold as a Marker of Tuberculosis (TB) Disease Severity: Implications for TB Treatment Stratification
Xpert MTB/RIF循环阈值作为结核病（TB）疾病严重程度的标志物：对结核病治疗分层的启示
Daniel J Grint and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e126–e134, https://doi.org/10.1093/cid/ciaf527
49
The Role of β-Lactam Antibiotics in Treating Mycobacterium abscessus: From Laboratory Insights to Clinical Applications and the Case for Clinical Trials
β-内酰胺类抗生素在治疗脓肿分枝杆菌中的作用：从实验室见解到临床应用及开展临床试验的必要性
Khalid M Dousa and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e135–e145, https://doi.org/10.1093/cid/ciaf547
Pediatric and Maternal Infectious Diseases（儿科与孕产妇传染病）
50
Efficacy, Immunogenicity, and Safety of an Investigational Maternal Respiratory Syncytial Virus Prefusion F Protein–Based Vaccine
一种研究性孕产妇呼吸道合胞病毒融合前F蛋白疫苗的疗效、免疫原性和安全性
Peyman Banooni and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e146–e155, https://doi.org/10.1093/cid/ciaf033
51
Hepatotoxicity Among People With HIV and Receiving Isoniazid Preventive Therapy in Pregnancy and Postpartum: The Role of Antiretroviral Regimen and Pharmacogenetics
HIV感染者在孕期和产后接受异烟肼预防性治疗时的肝毒性：抗逆转录病毒治疗方案和药物基因组学的作用
Grace Montepiedra and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e156–e164, https://doi.org/10.1093/cid/ciaf198
52
Transplacental Transfer of Lumefantrine, Mefloquine, and Piperaquine: A Comparison of Concentrations in Mothers, Neonates, and Cord Blood
青蒿素、甲氟喹和哌喹的胎盘转运：母亲、新生儿和脐带血中浓度的比较
Makoto Saito and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e165–e173, https://doi.org/10.1093/cid/ciaf552
53
Why Did the Antimalarial Drug Cross the Placenta?
抗疟药为何要穿过胎盘？
Stephen J Rogerson and Holger W Unger
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e174–e175, https://doi.org/10.1093/cid/ciaf553
Viral Infections（病毒性传染病）
54
Kinetics and Predictors of Hepatitis B Surface Antigen Loss After Commencing Hepatitis B Virus (HBV)–Active Antiretroviral Therapy in the Setting of HIV and Chronic HBV Coinfection
HIV和慢性乙型肝炎病毒（HBV）共感染患者开始使用HBV活性抗逆转录病毒治疗后乙型肝炎表面抗原消失的动力学和预测因素
Jennifer Audsley and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e176–e184, https://doi.org/10.1093/cid/ciaf281
55
Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections
患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病
Lauren A Powers and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e185–e190, https://doi.org/10.1093/cid/ciaf285
Correspondence（读者来信）
56
Unveiling Latent Risk Patterns in Antimicrobial-Resistant Bacteremia: A Deeper Look at Pathogen-Specific Mortality
揭示抗菌药物耐药性菌血症中的潜在风险模式：深入探究病原体特异性死亡率
Yuan-Ti Lee and Shiuan-Chih Chen
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e191, https://doi.org/10.1093/cid/ciaf493
57
Resistance to Antibiotics With High Empiric Treatment Relevance Explains Attributable Mortality Across 110 Pathogen-antibiotic Combinations
对经验性治疗具有高度相关性的抗生素耐药性可解释110种病原体 - 抗生素组合的归因死亡率
Kevin A Brown and Nick Daneman
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e191–e192, https://doi.org/10.1093/cid/ciaf494
58
Culture Clash: Dual-Pathogen Endocarditis and the Metagenomic Next-Generation Sequencing Studies We Need
文化冲突：双病原体心内膜炎以及我们所需的宏基因组下一代测序研究
Carl Boodman and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e193–e195, https://doi.org/10.1093/cid/ciaf518
59
Metagenomic Next-Generation Sequencing and Cardiovascular Infections: Promise and Pitfalls of Polymicrobial Detection
宏基因组下一代测序与心血管感染：多微生物检测的前景与陷阱
Sarwat Khalil and M Rizwan Sohail
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e196, https://doi.org/10.1093/cid/ciaf519
60
It Is Time to Go Beyond the Association Between Colistin and Meropenem for Invasive Carbapenem-Resistant Acinetobacter baumannii Infections
是时候超越多粘菌素和美罗培南联合治疗侵袭性碳青霉烯耐药鲍曼不动杆菌感染了
Alberto Enrico Maraolo and Giancarlo Ceccarelli
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e197–e198, https://doi.org/10.1093/cid/ciaf533
61
Actually, It May be Time to Return to Colistin and Meropenem in Some Patients Infected With Carbapenem-resistant Acinetobacter baumannii (CRAB)
实际上，对于某些感染碳青霉烯耐药鲍曼不动杆菌（CRAB）的患者，或许是时候重新使用多粘菌素和美罗培南了
Jason M Pogue and Keith S Kaye
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e198–e199, https://doi.org/10.1093/cid/ciaf534
62
COVID-19 and Bacterial Pneumonia: Protective Effect or Diagnostic Bias?
COVID-19和细菌性肺炎：保护作用还是诊断偏差？
Duygu Aydın and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e200, https://doi.org/10.1093/cid/ciaf539
63
Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections: A Follow Up
患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病：后续研究
John C Hu and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e200–e201, https://doi.org/10.1093/cid/ciaf540
64
Long-Acting Cabotegravir/Rilpivirine in Viremic People With HIV: Bumpy Road to Perfection
长效卡博特韦/利匹韦林用于病毒载量阳性的HIV感染者：通往完美的坎坷之路
Beatrice Barda and Marco Bongiovanni
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e201–e202, https://doi.org/10.1093/cid/ciaf482
65
Beyond the Sequence: Operationalizing Whole-Genome Sequencing for Real-time Infection Control in Low- and Middle-Income-Country Healthcare Settings Healthcare Settings
超越序列：在中低收入国家医疗环境中实际应用全基因组测序进行实时感染控制
Schawanya Kaewpitoon Rattanapitoon and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e202–e203, https://doi.org/10.1093/cid/ciaf535
66
Reassessing Adherence Trajectories in Multidrug-Resistant Tuberculosis: Recovery Advantage and Hidden Biases
重新评估耐多药结核病的依从性轨迹：康复优势和隐藏偏差
Shiuan-Chih Chen and Chun-Chieh Chen
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e203–e204, https://doi.org/10.1093/cid/ciaf536
67
Metagenomic Sequencing of Blood Culture Broth for Diagnosing Fastidious Endocarditis
血培养肉汤宏基因组测序用于诊断苛养性心内膜炎
Po-Hsiu Huang and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e204–e205, https://doi.org/10.1093/cid/ciaf554
Corrections（更正）
68
Correction to: Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections
《患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病》更正
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e206, https://doi.org/10.1093/cid/ciaf572
69
Correction to: Treatment Outcomes With an Oral Short Course Regimen for Rifampicin-resistant Tuberculosis in a High HIV Prevalence, Programmatic Setting in South Africa
《南非高HIV流行率、项目化环境中口服短程利福平耐药结核病治疗方案的治疗结果》更正
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e207, https://doi.org/10.1093/cid/ciaf711
Clinical Infectious Diseases Volume 82 Issue Supplement_1
临床传染病学 82卷 增刊1期
https://academic.oup.com/cid/issue/82/Supplement_1
SUPPLEMENT（增刊）
Laboratory and Point-of-care Testing to Detect Chlamydia trachomatis and Neisseria gonorrhoeae: Review of the Available Evidence
实验室及即时检测技术用于检测沙眼衣原体和淋病奈瑟菌：现有证据综述
SUPPLEMENT ARTICLES（增刊论著）
1
Evidence Review for Centers for Disease Control and Prevention Guidance Development on the Detection of Chlamydia trachomatis and Neisseria gonorrhoeae
美国疾病控制与预防中心沙眼衣原体和淋病奈瑟菌检测指南制定证据综述
Amanda C Smith and Ellen N Kersh
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S1–S5, https://doi.org/10.1093/cid/ciaf665
2
Narrative Review of Chlamydia trachomatis Culture, Viability Testing, and Sequencing Methods
沙眼衣原体培养、活性检测及测序方法的叙述性综述
Alana K Sterkel and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S6–S12, https://doi.org/10.1093/cid/ciaf697
3
Culture and Identification of Neisseria gonorrhoeae: A Narrative Review of Current Laboratory Methods
淋病奈瑟菌培养与鉴定：当前实验室方法叙述性综述
Olusegun O Soge and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S13–S18, https://doi.org/10.1093/cid/ciaf698
4
Review of the Performance of Laboratory-Based Molecular Diagnostics for Chlamydia trachomatis and Neisseria gonorrhoeae
实验室分子诊断技术检测沙眼衣原体和淋病奈瑟菌的性能综述
Megan Crumpler and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S19–S35, https://doi.org/10.1093/cid/ciaf696
5
Review of Methods for Detecting Antimicrobial Resistance of Neisseria gonorrhoeae
淋病奈瑟菌抗菌药物耐药性检测方法综述
Kara K Mitchell and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S36–S42, https://doi.org/10.1093/cid/ciaf706
6
Point-of-care Tests for Chlamydia trachomatis and Neisseria gonorrhoeae: Review of the Literature
沙眼衣原体和淋病奈瑟菌即时检测技术文献综述
Yukari C Manabe and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S43–S51, https://doi.org/10.1093/cid/ciaf699
Clinical Infectious Diseases Volume 82 Issue 2
临床传染病学 82卷 2期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时代的传染病技艺）
1
Interior of the Old Jersey Prison Ship in the Revolutionary War
美国革命战争中老泽西监狱船的内部景象
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Page i, https://doi.org/10.1093/cid/ciaf693
In the Literature（本期精选）
2
In the Literature
本期精选
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages ii–v, https://doi.org/10.1093/cid/ciag011
IDSA 2025 Collections Editorial（美国传染病学会2025年专题合集社论）
3
2025 Content Collections from the IDSA Journals
IDSA期刊2025年内容合集
Roger Bedimo and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 185–186, https://doi.org/10.1093/cid/ciag041
State-of-the-Art Review（前沿综述）
4
State-of-the-Art Review: Chagas Disease—an Enduring Challenge
前沿综述：恰加斯病——一个持续存在的挑战
Nelson Iván Agudelo Higuita and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 187–205, https://doi.org/10.1093/cid/ciaf654
IDSA Features（美国传染病学会特色内容）
5
Policy Recommendations to Support Equitable Access to Long-Acting Injectables for HIV Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association
支持公平获取用于艾滋病毒预防和治疗的长效注射剂的政策建议：美国传染病学会与艾滋病毒医学协会的政策文件
Julia L Marcus and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 206–211, https://doi.org/10.1093/cid/ciae648
Voices of ID（传染病之声）
6
A “Terminal Infection”
“绝症感染”
Jennifer Furin
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 212–214, https://doi.org/10.1093/cid/ciaf332
Invited Commentary（特邀评论）
7
A Rapid Test to Differentiate Viral From Bacterial Infections: Searching for the Holy Grail
区分病毒与细菌感染的快速检测：寻找“圣杯”
Lao-Tzu Allan-Blitz and Jeffrey D Klausner
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 215–218, https://doi.org/10.1093/cid/ciaf585
Bacterial Infections（细菌感染）
8
Nonoperative Versus Neurosurgical Treatment of Brain Abscess: An Emulated Trial Nested Within a Nationwide, Population-Based Cohort
脑脓肿的非手术治疗与神经外科治疗：一项基于全国人群队列的模拟试验
Emilie Marie Eriksen and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 219–227, https://doi.org/10.1093/cid/ciaf304
9
What Is the Impact of Anti-Enterococcal Empirical Therapy on Survival of Patients With Enterococcal Bloodstream Infections?
抗肠球菌经验性治疗对肠球菌血流感染患者生存率的影响是什么？
Linda Bussini and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 228–237, https://doi.org/10.1093/cid/ciaf323
10
Adjunctive Fosfomycin for the Treatment of Staphylococcus aureus Bacteremia: A Pooled Post Hoc Analysis of Individual Participant Data From 2 Randomized Trials
辅助使用磷霉素治疗金黄色葡萄球菌菌血症：两项随机试验个体参与者数据的汇总事后分析
Francesc Escrihuela-Vidal and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 238–245, https://doi.org/10.1093/cid/ciaf387
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
11
Kinetics of Non-nucleoside Reverse Transcriptase Inhibitor Resistance-associated Mutations in HIV-1 Proviral Cellular Reservoirs in Non-nucleoside Reverse Transcriptase Inhibitor-experienced Persons
在接受过非核苷类逆转录酶抑制剂治疗的HIV-1感染者中，非核苷类逆转录酶抑制剂耐药相关突变在HIV-1前病毒细胞储存库中的动力学
Thomas Drumel and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 246–251, https://doi.org/10.1093/cid/ciaf430
12
Impact of Different Integrase Strand Transfer Inhibitors on Body Mass Index Among People With HIV Who Newly Started Antiretroviral Therapy in Shenzhen, China: A Real-World Data Analysis
中国深圳新开始抗逆转录病毒治疗的HIV感染者使用不同整合酶链转移抑制剂对体重指数的影响：一项现实数据分析
Lukun Zhang and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 252–261, https://doi.org/10.1093/cid/ciaf466
13
Consequences of Stopping Antiretroviral Treatment in a Persistently Seronegative Individual with HIV-1
HIV-1持续血清阴性个体停止抗逆转录病毒治疗的后果
Marc Wirden and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 262–264, https://doi.org/10.1093/cid/ciaf422
14
Approaches to the Management of Virologic Failure on Dolutegravir-Based Antiretroviral Therapy in the 50 Countries With the Highest Adult HIV Prevalence
在成人HIV患病率最高的50个国家中，多替拉韦为基础的抗逆转录病毒治疗出现病毒学失败的治疗方法
Cameron T Nutt and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 265–273, https://doi.org/10.1093/cid/ciaf444
Mycobacterial Infections（结核分枝杆菌感染）
15
Retrospective Cohort Analysis for Identification of Discordant Rifampicin-resistant Xpert MTB/RIF Assay Results in South Kivu, Eastern Democratic Republic of the Congo, a High Burden Tuberculosis Setting
刚果民主共和国东部南基伍这一结核病高负荷地区，识别利福平耐药不一致的Xpert MTB/RIF检测结果的回顾性队列分析
Bertin C Bisimwa and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 274–281, https://doi.org/10.1093/cid/ciaf451
16
Prevention of Tuberculosis in Patients Treated With Biological Therapies: 20 Years' Experience in a Specialized Tuberculosis Clinic in a Low-prevalence Country
生物疗法治疗患者中结核病的预防：某低流行国家一个专科结核病诊所20年的经验
Sandra Pérez-Recio and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 282–290, https://doi.org/10.1093/cid/ciaf491
17
Reducing Household Tuberculosis Transmission: A Pilot Cluster-Randomized Controlled Trial
减少家庭内结核病传播：一项试点整群随机对照试验
Cinthya Ruiz-Tagle and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 291–298, https://doi.org/10.1093/cid/ciaf526
18
(Un)masking Tuberculosis
（揭开）结核病的“面具”
Joseph N Burzynski and Neil W Schluger
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 299–300, https://doi.org/10.1093/cid/ciaf528
19
Estimating the Accuracy and Additionality of TB-LAM to Diagnose TB in Children Without HIV (AccuLAM)
评估TB-LAM在无HIV儿童中诊断结核病的准确性和额外价值（AccuLAM）
Lucía CarratalàCastro and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 301–303, https://doi.org/10.1093/cid/ciaf525
Sexually Transmitted Infections（性传播感染）
20
Potential Impact of Doxycycline Post-exposure Prophylaxis Prescribing Strategies on Incidence of Bacterial Sexually Transmitted Infections
多西环素暴露后预防用药策略对细菌性性传播感染发病率的影响
Michael W Traeger and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 304–311, https://doi.org/10.1093/cid/ciad488
21
Filling in the Gaps: Updates on Doxycycline Prophylaxis for Bacterial Sexually Transmitted Infections
填补空白：多西环素预防细菌性性传播感染的最新进展
Aniruddha Hazra and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 312–320, https://doi.org/10.1093/cid/ciae062
22
Reported Neurologic Manifestations Among Persons With Syphilis by Stage of Infection—12 States, 2019–2022
2019-2022年12个州按感染阶段划分的梅毒患者报告的神经系统表现
Sarah B Wondmeneh and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 321–325, https://doi.org/10.1093/cid/ciaf015
Viral Infections（病毒性感染）
23
Investigating the Role of Cytomegalovirus as a Cause of Stillbirths and Child Deaths in Low- and Middle-Income Countries Through Postmortem Minimally Invasive Tissue Sampling
通过死后微创组织采样，调查巨细胞病毒在低收入和中等收入国家死胎和儿童死亡原因中的作用
Sithembiso Velaphi and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 326–336, https://doi.org/10.1093/cid/ciaf098
Photo Quiz（影像问答）
24
Bursting at the Seams
“撑破”
Maxwell Olenski and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 337–340, https://doi.org/10.1093/cid/ciaf488
Viral Infections（病毒性感染）
25
Clinical and Epidemiological Investigation of Vaccine-Derived Poliovirus Type 2 Outbreak in Pakistan During 2019–2021
2019-2021年巴基斯坦2型疫苗衍生脊髓灰质炎病毒疫情的临床和流行病学调查
Nayab Mehmood and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 341–351, https://doi.org/10.1093/cid/ciaf151
26
Inactivated Polio Vaccine Must Be an Essential Part of Polio Eradication
灭活脊髓灰质炎疫苗必须是根除脊髓灰质炎的重要组成部分
Konstantin Chumakov and Stanley A Plotkin
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 352–353, https://doi.org/10.1093/cid/ciaf215
Photo Quiz（影像问答）
27
Intracranial Lesion in a Patient With Chronic Myeloid Leukemia
慢性髓性白血病患者颅内病变
Mohammed Shakeel Sillat and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 354–357, https://doi.org/10.1093/cid/ciaf441
Viral Infections（病毒性感染）
28
Respiratory Syncytial Virus Co-Detection With Other Respiratory Viruses Is Not Significantly Associated With Worse Clinical Outcomes Among Children Aged <2 Years: New Vaccine Surveillance Network, 2016–2020
在<2岁的婴幼儿中，呼吸道合胞病毒与其他呼吸道病毒共同检测与临床预后恶化无显著关联：2016-2020年新疫苗监测网络数据
Justin Z Amarin and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 358–365, https://doi.org/10.1093/cid/ciaf194
29
Transfer of Herpes Simplex Virus Type 1 (HSV-1) Specific T Cells in a Pediatric Patient Post-HSCT With Severe, Acyclovir-resistant HSV-1 Infection
一例异基因造血干细胞移植后严重、阿昔洛韦耐药的单纯疱疹病毒1型（HSV-1）感染患儿的HSV-1特异性T细胞的输注
Astrid Wintering and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 366–369, https://doi.org/10.1093/cid/ciaf125
Clinical Trials（临床实验）
30
Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial
干扰素-α鼻喷雾剂预防可降低癌症患者新冠病毒感染率：一项随机、双盲、安慰剂对照试验
Michelle K Yong and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e208–e216, https://doi.org/10.1093/cid/ciaf409
31
A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18–64 Years of Age at Increased Risk of Pneumococcal Disease, STRIDE-8
一项3期随机试验，调查V116（一种成人特异性肺炎球菌结合疫苗）在未接种过肺炎球菌疫苗且患肺炎球菌疾病风险增加的18-64岁年龄段成人中的安全性、耐受性和免疫原性，STRIDE-8试验
Paul T Scott and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e217–e226, https://doi.org/10.1093/cid/ciaf604
32
Effect of Direct-from-blood Bacterial Testing on Antibiotics Administration in Adults Presenting With Acute Infection: A Randomized Trial
直接从血液进行细菌检测对急性感染成年患者抗生素给药的影响：一项随机试验
David C Gaston and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e227–e235, https://doi.org/10.1093/cid/ciaf677
33
The Tantalizing Pursuit for a Perfect Diagnostic Test: Balancing Innovation With Stewardship
对完美诊断检测的诱人追求：平衡创新与管理
K C Coffey and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e236–e238, https://doi.org/10.1093/cid/ciaf674
Global Health and Neglected Tropical Diseases（全球健康与被忽视的热带病）
34
Diagnostic Accuracy of Tuberculosis Screening Tests in a Prospective Multinational Cohort: Chest Radiography With Computer-Aided Detection, Xpert Tuberculosis Host Response, and C-Reactive Protein
在一项前瞻性多国队列研究中，结核病筛查试验的诊断准确性：计算机辅助检测的胸部X光片、Xpert结核宿主反应检测和C反应蛋白
Rebecca Crowder and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e239–e247, https://doi.org/10.1093/cid/ciae549
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
35
Risk Assessment in a Global CVD Prevention Cohort of People With HIV by PCE, PREVENT, and SCORE2
通过PCE、PREVENT和SCORE2对全球心血管疾病预防队列中艾滋病毒感染者进行风险评估
Steven K Grinspoon and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e248–e257, https://doi.org/10.1093/cid/ciaf542
36
REPRIEVE Analysis of New Cardiovascular Risk Calculators in HIV: Underpredicting Risk Means Preventing Fewer Heart Attacks
HIV新心血管风险计算器的REPRIEVE分析：低估风险意味着预防的心脏病发作更少
Matthew S Durstenfeld
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e258–e261, https://doi.org/10.1093/cid/ciaf543
37
Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study)
在病毒学抑制的HIV感染成人中，转换为比克替拉韦/恩曲他滨/丙酚替诺福韦与继续使用多替拉韦/拉米夫定后的炎症和代谢结局相当（INSTINCT/GESIDA10918研究）
Sergio Serrano-Villar and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e262–e274, https://doi.org/10.1093/cid/ciaf565
38
Tenofovir Alafenamide and Body Weight: Have We Finally Tipped the Scale?
丙酚替诺福韦与体重：我们最终是否打破了平衡？
John R Koethe
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e275–e277, https://doi.org/10.1093/cid/ciaf566
39
Long-Term Clinical, Immunologic, and Viral Reservoir Outcomes in Children Treated With VRC01LS and 10-1074 Monoclonal Antibodies in the Tatelo Study
在Tatelo研究中，接受VRC01LS和10-1074单克隆抗体治疗的儿童的长期临床、免疫学和病毒储存库结局
Gbolahan Ajibola and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e278–e285, https://doi.org/10.1093/cid/ciaf568
40
Trends in Persons Prescribed HIV Postexposure Prophylaxis in the United States, 2015–2023
2015-2023年美国开具HIV暴露后预防处方的患者趋势
John N Le and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e286–e295, https://doi.org/10.1093/cid/ciaf581
Immunocompromised Hosts（免疫功能低下宿主）
41
Epidemiology, Risk Factors, and Outcomes of Neutropenic Enterocolitis in Onco-Hematological Patients According to Chemotherapy Regimen
根据化疗方案分析肿瘤血液学患者中性粒细胞减少性肠结肠炎的流行病学、危险因素和预后
Anne-Sophie Brunel and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e296–e307, https://doi.org/10.1093/cid/ciaf134
42
An Analysis of Cytomegalovirus-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in Cytomegalovirus-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant
在一项3期随机、安慰剂对照试验中，分析来特莫韦预防对巨细胞病毒血清阳性异基因造血细胞移植受者巨细胞病毒特异性细胞介导免疫的影响
Genovefa A Papanicolaou and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e308–e315, https://doi.org/10.1093/cid/ciaf646
43
Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity for Prediction of Postprophylaxis CMV Disease in a Phase 3 Trial of Letermovir Versus Valganciclovir Prophylaxis in Donor CMV-Seropositive/Recipient CMV-Seronegative Kidney Transplant Recipients
在供体巨细胞病毒血清阳性/受体巨细胞病毒血清阴性的肾移植受者中，来特莫韦与缬更昔洛韦预防的3期试验中，巨细胞病毒（CMV）特异性细胞介导免疫对预防后CMV疾病的预测作用
Ajit P Limaye and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e316–e324, https://doi.org/10.1093/cid/ciaf632
44
The Role of Cytomegalovirus-Specific Cellular Immunity in Transplant Recipients with Letermovir Prophylaxis: To be Determined
来特莫韦预防移植受者中巨细胞病毒特异性细胞免疫的作用：有待确定
Yoichiro Natori and Martina Sester
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e325–e327, https://doi.org/10.1093/cid/ciaf633
45
IL12RB1 Deficiency Appearing in North America: Expanding the Clinical Phenotypes
北美出现的IL12RB1缺陷：拓展临床表型
Chen Wang and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e328–e331, https://doi.org/10.1093/cid/ciaf637
Vaccines（疫苗）
46
A Phase IV, Open-label, Single-Arm, Multicentric Clinical Trial for Evaluation of Human Papillomavirus 9vHPV Vaccine Immunogenicity in Men Who Have Sex With Men With HIV: GeSIDA Study 10 017
一项评估人乳头瘤病毒9vHPV疫苗在感染HIV的男男性行为者中免疫原性的IV期、开放标签、单臂、多中心临床试验：GeSIDA 10 017研究
Raquel Ron and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e332–e342, https://doi.org/10.1093/cid/ciaf435
47
Immunogenicity and Safety of the COVID-19 Messenger RNA Vaccine Coadministered With Influenza and 23-valent Pneumococcal Polysaccharide Vaccines
与流感疫苗和23价肺炎球菌多糖疫苗同时接种的COVID-19信使核糖核酸疫苗的免疫原性和安全性
Omid Rezahosseini and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e343–e351, https://doi.org/10.1093/cid/ciaf455
48
Intestinal Mucosal Immune Responses to Novel Oral Poliovirus Vaccine Type 2 in Healthy Newborns
健康新生儿对新型2型口服脊髓灰质炎疫苗的肠道黏膜免疫反应
Audrey Godin and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e352–e360, https://doi.org/10.1093/cid/ciaf484
49
Estimated Vaccine Effectiveness for Respiratory Syncytial Virus–Related Acute Respiratory Illness in Older Adults: Findings From the First Postlicensure Season
老年人呼吸道合胞病毒相关急性呼吸道疾病的估计疫苗有效性：首个上市后季节的研究结果
Sara Y Tartof and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e361–e370, https://doi.org/10.1093/cid/ciaf496
Sexually Transmitted Infections（性传播感染）
50
Systematic Review and Meta-analysis of the Association Between Mycoplasma genitalium and Pelvic Inflammatory Disease (PID)
生殖支原体与盆腔炎性疾病（PID）关联的系统综述和荟萃分析
Kay Htaik and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e371–e379, https://doi.org/10.1093/cid/ciae295
51
Sexually Transmitted Infection (STI)/HIV Testing, STIs, and HIV Pre-exposure Prophylaxis Use Among Men Who Have Sex With Men and Men Who Have Sex With Men and Women in the United States, 2019–2022
2019-2022年美国男男性行为者以及男男性行为者和女性性行为者中性传播感染（STI）/HIV检测、性传播感染和HIV暴露前预防用药情况
Guoyu Tao and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e380–e386, https://doi.org/10.1093/cid/ciae314
52
Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial Sexually Transmitted Infections: A Secondary Analysis of HPTN 083
卡博特韦在细菌性性传播感染情况下维持保护效力：HPTN 083的二次分析
Meredith E Clement and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e387–e395, https://doi.org/10.1093/cid/ciae572
Viral Infections（病毒性感染）
53
Comprehensive Analysis of Cardiovascular Events and Risk Factors in Patients Hospitalized With Respiratory Syncytial Virus
对因呼吸道合胞病毒感染住院患者的心血管事件和危险因素的综合分析
Paulina Sudnik and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e396–e403, https://doi.org/10.1093/cid/ciaf310
54
In Critical Condition: The Urgent Need to Support Mpox Therapeutic and Diagnostic Pipelines
处于危急状况：迫切需要支持猴痘治疗和诊断管线
Carmen Perez Casas and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e404–e408, https://doi.org/10.1093/cid/ciaf529
Correspondence（读者来信）
55
Caution in Interpreting INSTIs and Weight in Observational Studies
在观察性研究中解读整合酶抑制剂与体重关系时需谨慎
Esteban Martínez
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Page e409, https://doi.org/10.1093/cid/ciaf569
56
Weight Trajectories With Integrase Inhibitors: Unaddressed Insights and Limitations in a Chinese Cohort
整合酶抑制剂与体重变化轨迹：中国队列中未解决的见解和局限性
Yuan-Ti Lee and Shiuan-Chih Chen
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e409–e410, https://doi.org/10.1093/cid/ciaf570
57
Real-World Evidence as a Complement to Randomized Trials in Interpreting Weight Gain on Modern INSTI Regimens
现实证据作为随机试验的补充，用于解读现代整合酶抑制剂方案导致的体重增加
Xinsheng Wu and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e410–e411, https://doi.org/10.1093/cid/ciaf571
58
C-reactive Protein in TB Meningitis: Signal, Surrogate, or Saboteur?
结核性脑膜炎中的C反应蛋白：信号、替代指标还是破坏因素？
Patrick K Moonan and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e411–e412, https://doi.org/10.1093/cid/ciaf575
59
C-Reactive Protein in Tuberculous Meningitis: A Viable Biomarker for Individualized Care
结核性脑膜炎中的C反应蛋白：个体化护理的可行生物标志物
Lillian Tugume and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e412–e413, https://doi.org/10.1093/cid/ciaf576
60
The Win Ratio Should Be Complemented by Other Win Statistics to Provide a Comprehensive Picture of Relative and Absolute Treatment Effects: The Case Study of the REPRIEVE Trial
胜利比率应与其他胜利统计数据相结合，以全面呈现相对和绝对治疗效果：REPRIEVE试验案例研究
Melissa J Hardy and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e413–e414, https://doi.org/10.1093/cid/ciaf587
61
Small Effects, Big Impact: Multiple Win Measures Aid Interpretation, But Do Not Forget the Bigger Picture
效应虽小，影响重大：多种胜利衡量指标有助于解读，但不要忘记整体情况
Emma Davies Smith and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e414–e416, https://doi.org/10.1093/cid/ciaf588
62
Does Oral Antibiotic Switching Therapy Show Similar Efficacy to Intravenous Administration for Treating Infective Endocarditis?
口服抗生素转换疗法治疗感染性心内膜炎的疗效是否与静脉给药相似？
Jun Suzuki and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e416–e417, https://doi.org/10.1093/cid/ciaf598
63
Toward a Wider Use of Oral Antibiotic Switch in Infective Endocarditis
朝着更广泛地使用感染性心内膜炎口服抗生素转换疗法迈进
Romane Pouy and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e417–e418, https://doi.org/10.1093/cid/ciaf599
64
Operationalizing Sepsis Definitions With Artificial Intelligence: Toward Smarter Antibiotic Use
利用人工智能实现败血症定义的落地应用：迈向更明智的抗生素使用
James S Ford and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e418–e419, https://doi.org/10.1093/cid/ciaf601
65
Balancing Innovation in Artificial Intelligence With Practical Sepsis Definitions
平衡人工智能创新与实用的败血症定义
Chanu Rhee and Michael Klompas
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e419–e420, https://doi.org/10.1093/cid/ciaf602
66
Precision Prevention of Tuberculosis in Biologic Therapy: Lessons Beyond Screening Strategies
生物疗法中结核病的精准预防：筛查策略之外的启示
Shiuan-Chih Chen and Yuan-Ti Lee
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e420–e421, https://doi.org/10.1093/cid/ciaf559
67
Recalibrating COVID-19 Booster Policy: Lessons From Hybrid Immunity and Global Equity Gaps
重新调整COVID-19加强针政策：从混合免疫和全球公平差距中吸取教训
Nathkapach K Rattanapitoon and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e421–e422, https://doi.org/10.1093/cid/ciaf605
Clinical Infectious Diseases Volume 82 Issue 3
临床传染病学 82卷 3期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时代的传染病技艺）
1
Dracunculiasis, 1674
1674年的麦地那龙线虫病
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Page i, https://doi.org/10.1093/cid/ciag089
In the Literature（文献聚焦）
2
In the Literature
文献聚焦
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages ii–iv, https://doi.org/10.1093/cid/ciag012
State-of-the-Art Review（前沿综述）
3
State-of-the-Art Review: Managing Vulvovaginal Candidiasis
前沿综述：外阴阴道念珠菌病的治疗
Riina Rautemaa-Richardson and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 371–382, https://doi.org/10.1093/cid/ciaf673
Ethics Rounds（伦理探讨）
4
CARB Your Enthusiasm: An Ethics-Informed Analysis for Clinicians of the US National Action Plan for Combating Antibiotic-Resistant Bacteria
谨慎对待抗生素：基于伦理学分析美国国家抗耐药菌行动计划对临床医生的启示
Hunter Jackson Smith and Chelsea Modlin
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 383–388, https://doi.org/10.1093/cid/ciaf478
Voices of ID（传染病之声）
5
Mothers
母亲们
Maria Koshy
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 389–390, https://doi.org/10.1093/cid/ciaf338
Bacterial Infections（细菌性感染）
6
The Impact of Synergistic Therapy Between Colistin and Meropenem on Outcomes of People With Pneumonia or Bloodstream Infection Due to Carbapenem-Resistant Gram-Negative Pathogens
多粘菌素与美罗培南联合治疗对碳青霉烯类耐药革兰氏阴性菌所致肺炎或血行感染患者预后的影响
Mariya Huralska and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 391–398, https://doi.org/10.1093/cid/ciaf398
7
We Cannot Overcome the Mediocrity of Colistin
我们无法忽视多粘菌素的平庸疗效
Jason C Gallagher
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 399–401, https://doi.org/10.1093/cid/ciaf592
8
Comparing Clinical, Microbiological, and Genetic Definitions of Relapse in Patients With Subsequent Episodes of Methicillin-resistant Staphylococcus aureus Bone and Joint Infection
比较耐甲氧西林金黄色葡萄球菌骨关节感染后续发作患者复发在临床、微生物学和遗传学上的定义
Kevin Bouiller and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 402–410, https://doi.org/10.1093/cid/ciaf448
9
Non-Klebsiella pneumoniae Carbapenemase Attributes of the Newer β-lactam/β-lactamase Inhibitors, Part 2: Burkholderia cepacia Complex, Stenotrophomonas maltophilia, and Acinetobacter baumannii
新型β-内酰胺/β-内酰胺酶抑制剂对非肺炎克雷伯菌碳青霉烯酶的抗菌特性，第二部分：洋葱伯克霍尔德菌复合群、嗜麦芽窄食单胞菌和鲍曼不动杆菌
Andrew J Fratoni and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 411–419, https://doi.org/10.1093/cid/ciaf403
Clinical Trials（临床试验）
10
Continuation Versus Temporary Interruption of Immunomodulatory Agents During Infections in Patients With Inflammatory Rheumatic Diseases: A Randomized Controlled Trial
炎症性风湿性疾病患者感染期间继续使用与暂时停用免疫调节剂的随机对照试验
Merel A A Opdam and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 420–426, https://doi.org/10.1093/cid/ciaf442
11
Effectiveness of Nebulized Bronchodilator-Enhanced Sputum Induction in Thai Patients With Presumed Pulmonary Tuberculosis: A Randomized Controlled Trial (NeB-TB Trial)
泰国疑似肺结核患者中雾化支气管扩张剂增强痰诱导的有效性：一项随机对照试验（NeB-TB试验）
Pichanon Mingchay and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 427–435, https://doi.org/10.1093/cid/ciaf580
12
Bone Biopsy not Superior to Ulcer Bed Biopsy–guided Antibacterial Therapy on Remission of Diabetic Foot Osteomyelitis: A Randomized Controlled Trial
在指导用于缓解糖尿病足骨髓炎的抗菌治疗方面骨活检并不优于溃疡床活检：一项随机对照试验
Rimke S Lagrand and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 436–442, https://doi.org/10.1093/cid/ciaf684
13
Do We Need a Bone Biopsy for Managing Diabetic Foot Osteomyelitis?
我们是否需要对糖尿病足骨髓炎进行骨活检？
Eric M Senneville and Benjamin A Lipsky
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 443–445, https://doi.org/10.1093/cid/ciaf685
Critical Care and Sepsis（重症监护与败血症）
14
Contamination of Blood Cultures Drawn From Arterial Catheters Versus Venipuncture or Venous Catheters in Critically Ill Patients: A Systematic Review and Meta-analysis
危重患者从动脉导管与静脉穿刺或静脉导管采集血培养的污染情况：一项系统综述和荟萃分析
Takatoshi Koroki and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 446–452, https://doi.org/10.1093/cid/ciaf260
15
Reassessing Procalcitonin-Guided Antibiotic Therapy in Critically Ill Patients With Sepsis: Lessons From the ADAPT-Sepsis Trial
重新评估降钙素原指导的败血症危重患者抗生素治疗：来自ADAPT-败血症试验的启示
Simran Gupta and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 453–458, https://doi.org/10.1093/cid/ciaf336
Infection Control and Hospital Epidemiology（传染病控制与医院流行病学）
16
Effectiveness and Safety of Methods to Prevent Bloodstream and Other Infections and Noninfectious Complications Associated With Peripherally Inserted Central Catheters: A Systematic Review and Meta-Analysis
预防经外周静脉置入中心静脉导管相关血行感染及其他感染和非感染性并发症的方法的有效性和安全性：一项系统综述和荟萃分析
Andreea Dobrescu and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 459–472, https://doi.org/10.1093/cid/ciaf063
17
Using Generative Artificial Intelligence for Healthcare-Associated Infection Surveillance
利用生成式人工智能进行医院感染监测
Daniel J Morgan and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 473–479, https://doi.org/10.1093/cid/ciaf619
18
Artificial Intelligence and the Future of Healthcare-Associated Infection Surveillance: Bridging Precision, Partnership, Practice, and People
人工智能与医院感染监测的未来：融合精准、合作、实践与人文
Mamdooh Alzyood
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 480–483, https://doi.org/10.1093/cid/ciaf620
Infections in Older Adults（老年传染病学）
19
Evaluation of Influenza Antiviral Prophylaxis for Long-term Care Residents: A Systematic Review and Meta-Analysis
长期护理机构居民流感抗病毒预防的效果评价：一项系统综述和荟萃分析
Ryan Hanula and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 484–493, https://doi.org/10.1093/cid/ciaf101
20
Implementation of Diagnostic Stewardship to Improve Urinary Tract Infection Antibiotic Use Across 3 Medical Centers
在三家医疗中心实施诊断管理以改善尿路感染抗生素的使用
Kimberly C Claeys and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 494–500, https://doi.org/10.1093/cid/ciaf411
Pediatric and Maternal Infectious Diseases（儿科与孕产妇传染病）
21
Adverse Events of First-Line Therapy for Pediatric Tuberculosis: A Systematic Review and Meta-Analysis
儿童结核病一线治疗的不良反应：一项系统综述和荟萃分析
Michael Prodanuk and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 501–512, https://doi.org/10.1093/cid/ciaf152
22
The Impact of Pregnancy on Tuberculosis Treatment Outcomes: An Analysis of Brazilian National Surveillance Data 2016–2022
妊娠对结核病治疗效果的影响：基于2016-2022年巴西国家监测数据的分析
Silvia S Chiang and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 513–521, https://doi.org/10.1093/cid/ciaf233
Photo Quiz（影像问答）
23
Persistent Fever and Back Pain After Liver Transplantation
肝移植后持续发热和背痛
Toshiyuki Kishida and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 522–525, https://doi.org/10.1093/cid/ciaf489
Pediatric and Maternal Infectious Diseases（儿科与孕产妇传染病）
24
Stool Processing Methods for Xpert Ultra Testing in Childhood Tuberculosis: A Prospective, Multicountry Accuracy Study
儿童结核病Xpert Ultra检测的粪便处理方法：一项前瞻性、多国准确性研究
Devan Jaganath and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 526–534, https://doi.org/10.1093/cid/ciaf289
Photo Quiz（影像问答）
25
A Bloom Beneath the Skin
皮下绽放之花
Yi Rong Chew and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 535–538, https://doi.org/10.1093/cid/ciaf550
Vector-Borne Diseases（虫媒传染病）
26
Trends in Anaplasmosis Over the Past Decade: A Review of Clinical Features, Laboratory Data, and Outcomes
过去十年无形体病趋势：临床特征、实验室数据和预后回顾
Silpita Katragadda and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 539–547, https://doi.org/10.1093/cid/ciaf171
27
Completion of Paired Serological Testing Algorithms for Spotted Fever Rickettsiosis and Ehrlichiosis, North Carolina: 2017–2020
斑点热立克次体病和埃里希体病配对血清学检测算法的完成情况，北卡罗来纳州：2017-2020年
Huipeng Liao and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 548–555, https://doi.org/10.1093/cid/ciaf176
COVID-19/SARS-COV-2（新冠肺炎/严重急性呼吸综合征冠状病毒2型）
28
Effect of Metformin on the Risk of Post-COVID-19 Condition Among Individuals With Overweight or Obese: A Population-based Retrospective Cohort Study
二甲双胍对超重或肥胖人群患新冠后综合征风险的影响：一项基于人群的回顾性队列研究
Ubonphan Chaichana and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e423–e432, https://doi.org/10.1093/cid/ciaf429
29
Preventing Long COVID With Metformin
使用二甲双胍预防新冠长期症状
Carolyn T Bramante and David R Boulware
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e433–e435, https://doi.org/10.1093/cid/ciaf700
30
Effectiveness of COVID-19 Vaccination and Prior Infections to Reduce Long COVID Risk During the Pre-Omicron and Omicron Periods
COVID-19疫苗接种和既往感染在奥密克戎变异株出现前及奥密克戎时期降低新冠长期症状风险的有效性
Sara Carazo and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e436–e445, https://doi.org/10.1093/cid/ciaf549
31
International Collaboration to Develop and Harmonize Drug Interaction Guidance for Nirmatrelvir/Ritonavir During COVID-19: Lessons Learned for Future Pandemic Preparedness
国际合作制定并统一新冠期间奈玛特韦/利托那韦药物相互作用指南：为未来大流行准备汲取的经验教训
Safia Kuriakose and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e446–e454, https://doi.org/10.1093/cid/ciaf606
Endovascular Infections（血管内感染）
32
Antifungal Therapy in Candida Infective Endocarditis: A Comparison of Echinocandins and Other Treatment Regimens in a Nationwide Cohort Study
念珠菌感染性心内膜炎的抗真菌治疗：一项全国队列研究中棘白菌素与其他治疗方案比较
Siri Kurland and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e455–e461, https://doi.org/10.1093/cid/ciaf312
33
Should We Extend the Use of Oral Antibiotics in Infective Endocarditis? The ENDO-ORAL Study
我们是否应延长感染性心内膜炎口服抗生素的使用？ENDO-ORAL研究
Benoit Rallet and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e462–e470, https://doi.org/10.1093/cid/ciaf452
34
Rethinking the Routine: Are Repeat Blood Cultures Necessary After Completion of Infective Endocarditis Treatment?
重新思考常规做法：感染性心内膜炎治疗完成后是否需要重复血培养？
Jean Regina and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e471–e474, https://doi.org/10.1093/cid/ciaf617
35
Posttreatment Blood Cultures in Patients With Infective Endocarditis: Valuable, Inconsequential, or Worse?
感染性心内膜炎患者治疗后的血培养：有价值、无关紧要还是有害？
Daniel C DeSimone and Larry M Baddour
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e475–e476, https://doi.org/10.1093/cid/ciaf618
Fungal Infections（真菌感染）
36
Fungal Meningitis in US Patients Who Received Epidural Anesthesia in Matamoros, Mexico
在墨西哥马塔莫罗斯接受硬膜外麻醉的美国患者中的真菌性脑膜炎
Dallas J Smith and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e477–e484, https://doi.org/10.1093/cid/ciaf399
37
Empirical Antifungal Treatment of Critically ⅢPatients With Influenza-Associated Acute Respiratory Distress Syndrome: A Propensity Score Weighted Observational Study
流感相关急性呼吸窘迫综合征危重患者的经验性抗真菌治疗：一项倾向评分加权观察性研究
Stefan Hatzl and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e485–e493, https://doi.org/10.1093/cid/ciaf507
38
Is Empirical Antifungal Therapy the Next Path Forward in Patients With Influenza-Associated ARDS?
经验性抗真菌治疗是否是流感相关急性呼吸窘迫综合征患者的下一步治疗方向？
Florian Reizine and Jean-Pierre Gangneux
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e494–e496, https://doi.org/10.1093/cid/ciaf508
39
Valley Fever in Central California: Diagnosis is Not the Finish Line, the Real Gap is Longitudinal Care
加利福尼亚州中部山谷热：诊断并非终点，真正的差距在于纵向护理
Geetha Sivasubramanian
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e497–e502, https://doi.org/10.1093/cid/ciaf728
Hepatitis（肝炎）
40
The Hepatitis C Cascade of Care for Opioid Agonist Therapy Recipients in Australia
澳大利亚接受阿片类激动剂治疗者的丙型肝炎治疗流程
Samara Griffin and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e503–e510, https://doi.org/10.1093/cid/ciaf352
41
Trends in Hepatitis C Virus Infection Prevalence Among People With HIV in Spain Over 2 Decades (2002–2023)
西班牙20多年来（2002-2023年）HIV感染者中丙型肝炎病毒感染流行率的趋势
Juan Berenguer and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e511–e520, https://doi.org/10.1093/cid/ciaf407
42
Gaps in the Hepatitis C Prenatal and Postpartum Care Cascade: Rationale for Treatment in Pregnancy
丙型肝炎围产期和产后治疗流程中的差距：孕期治疗的理由
Andrew B Mendlowitz and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e521–e533, https://doi.org/10.1093/cid/ciaf578
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
43
Combined Use of Ibalizumab and Lenacapavir for the Treatment of Multidrug-resistant HIV-1: A Case Series
艾巴利珠单抗和来那卡帕韦联合治疗多重耐药HIV-1：病例系列研究
Charlotte Rolle and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e534–e540, https://doi.org/10.1093/cid/ciaf597
44
New Strategies for a Vexing Problem: Injectables to the Rescue for People With Multidrug-Resistant HIV
棘手问题的新策略：注射剂助力多重耐药HIV感染者
William R Short and Onyema E Ogbuagu
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e541–e543, https://doi.org/10.1093/cid/ciaf600
45
The Bounce-back Effect: What Happens After Cessation of Low-dose Semaglutide in People With HIV
反弹效应：HIV感染者停用低剂量司美格鲁肽后会发生什么
Kristine M Erlandson and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e544–e548, https://doi.org/10.1093/cid/ciaf652
46
Infections After Kidney Transplantation From Donors With HIV to Recipients With HIV
HIV阳性供体肾脏移植给HIV阳性受者后的感染情况
Elizabeth C Arant and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e549–e557, https://doi.org/10.1093/cid/ciaf656
47
Infections After Kidney Transplantation from Donors with HIV to Recipients with HIV: Insights, Prevention, and the Path Forward
HIV阳性供体肾脏移植给HIV阳性受者后的感染情况：见解、预防和未来方向
Abhay Dhand and Stephanie M Pouch
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e558–e560, https://doi.org/10.1093/cid/ciaf657
Respiratory Infections（呼吸道传染病）
48
Multimorbidity Profiles and Severe In-Hospital Outcomes in Adults With Respiratory Syncytial Virus
成人呼吸道合胞病毒感染的多病共存情况及严重院内结局
Kevin C Ma and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e561–e570, https://doi.org/10.1093/cid/ciaf405
49
Characterizing Treatment Adherence Trajectories in the endTB Multisite Cohort of Drug-Resistant Tuberculosis Patients: An Application of Group-Based Trajectory Modeling
在endTB多站点耐药结核病患者队列中描述治疗依从性轨迹：基于组别的轨迹建模应用
Stephanie Law and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e571–e579, https://doi.org/10.1093/cid/ciaf467
50
Severity of Clinical Presentation and Outcomes in Hospitalized Adult People With Influenza by Type and Subtype, United States—2017–2020
2017 - 2020年美国按流感类型和亚型划分的住院成人流感患者临床表现严重程度及预后
Seana Cleary and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e580–e588, https://doi.org/10.1093/cid/ciaf545
51
Reported Tuberculosis Symptoms: An Inadequate Classifier of Disease State
报告的结核病症状：疾病状态分类的不足指标
Nicky McCreesh and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e589–e594, https://doi.org/10.1093/cid/ciaf611
Sexually Transmitted Infections（性传播感染）
52
Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity—IVY Network, 26 Hospitals, 18 October 2023–9 March 2024
2023 - 2024年更新版（单价XBB.1.5）新冠疫苗对SARS-CoV-2奥密克戎XBB和BA.2.86/JN.1谱系住院的有效性及临床严重程度比较——IVY网络，26家医院，2023年10月18日 - 2024年3月9日
Kevin C Ma and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e595–e603, https://doi.org/10.1093/cid/ciae405
53
High Prevalence of Haemophilus ducreyi Among Patients With Suspected Primary syphilis in Malawi, 2019–2022
2019 - 2022年马拉维疑似原发性梅毒患者中杜克雷嗜血杆菌的高流行率
Mitch M Matoga and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e604–e611, https://doi.org/10.1093/cid/ciaf114
54
Characteristics Associated With Disseminated Gonococcal Infections vs Uncomplicated Gonorrhea: A California Case-control Study, 2021–2022
与播散性淋球菌感染（而非单纯性淋病）相关的特征：2021 - 2022年加利福尼亚病例对照研究
Kelly A Johnson and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e612–e615, https://doi.org/10.1093/cid/ciaf311
Viral Infections（病毒性感染）
55
Anal Human Papillomavirus Infection Progression to Disease Among Men Who Have Sex With Men
男男性行为者肛门人乳头瘤病毒感染进展为疾病的情况
Joel M Palefsky and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e616–e625, https://doi.org/10.1093/cid/ciaf584
Correspondence（读者来信）
56
Cardiac Complications of Mycoplasma pneumoniae: Overlooked Confounders, Biomarkers, and Host-Driven Shifts
肺炎支原体感染的心脏并发症：被忽视的混杂因素、生物标志物及宿主驱动的变化
Shiuan-Chih Chen and Ming-Cheng Lin
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e626–e627, https://doi.org/10.1093/cid/ciaf609
57
Mycoplasma pneumoniae–Associated Cardiac Complications Revisited
重新审视肺炎支原体相关心脏并发症
Daniel Grupel and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e627–e628, https://doi.org/10.1093/cid/ciaf610
58
Screening for Anal Cancer Is Associated With Real Harms and Questionable Benefits
肛门癌筛查存在实际危害且益处存疑
Chris Kenyon
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Page e628, https://doi.org/10.1093/cid/ciaf613
59
Anal Cancer Screening: A Balanced Approach is Necessary
肛门癌筛查：需采取平衡的方法
Hayden S Andrews and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e628–e629, https://doi.org/10.1093/cid/ciaf614
60
Collateral Benefits and Methodological Limits of Respiratory Syncytial Virus Immunization for Infant Otitis Media and Antibiotic Use
呼吸道合胞病毒免疫接种对婴儿中耳炎和抗生素使用的附带益处及方法学局限
Tsai Ling Ting and Kai-Lun Sheu
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e629–e630, https://doi.org/10.1093/cid/ciaf640
61
Interpretation of Respiratory Syncytial Virus Immunization Impact on Pediatric Acute Otitis Media: Key Considerations
解读呼吸道合胞病毒免疫接种对儿童急性中耳炎的影响：关键考量因素
Inès Fafi and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e630–e631, https://doi.org/10.1093/cid/ciaf641
62
A Possible Increase in Penicillin-Resistant Strains of Treponema pallidum
梅毒螺旋体青霉素耐药菌株可能增加
Jun Suzuki and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e631–e632, https://doi.org/10.1093/cid/ciaf643
63
Surveillance of Resistance-Associated Mutations in Treponema pallidum
梅毒螺旋体耐药相关突变的监测
Kai-Hsiang Chen and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e632–e633, https://doi.org/10.1093/cid/ciaf645
64
Does Empirical Antifungal Therapy Reduce IAPA in Influenza-Associated ARDS? Methodological Concerns on Diagnosis, Surveillance, and Clinical Heterogeneity
经验性抗真菌治疗能否减少流感相关急性呼吸窘迫综合征（IAPA）的发生？诊断、监测和临床异质性方面的方法学问题
Ming Xue and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e633–e634, https://doi.org/10.1093/cid/ciaf661
65
Empirical Antifungal Therapy and IAPA in Influenza-Associated ARDS: Insights from Real-World Data
流感相关急性呼吸窘迫综合征中的经验性抗真菌治疗和IAPA：来自现实数据的见解
Stefan Hatzl and Robert Krause
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Page e634, https://doi.org/10.1093/cid/ciaf664
Clinical Infectious Diseases Volume 82 Issue Supplement_2
临床传染病学 82卷 增刊2期
https://academic.oup.com/cid/issue/82/Supplement_2
SUPPLEMENT（增刊）
Advancing Tuberculosis Research Through RePORT International: Enhancing Treatment Outcomes, Predicting Disease Progression, and Improving Diagnosis
通过结核病区域性前瞻性观察研究国际联盟（RePORT International）推动结核病研究：提高治疗效果、预测疾病进展及改善诊断
SUPPLEMENT ARTICLES（增补论著）
1
A Narrative Review of the Regional Prospective Observational Research in Tuberculosis International Consortium: Sharing Diverse Data and Specimens in the Fight Against Tuberculosis
结核病区域性前瞻性观察研究国际联盟的叙述性综述：在抗击结核病中共享多样数据和样本
Rajita Bhavaraju and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_2, 15 April 2026, Pages S53–S59, https://doi.org/10.1093/cid/ciag151
2
Long-term Sequelae of Pulmonary Tuberculosis: A Narrative Review
长期肺部结核后遗症：一项叙述性综述
Akshay N Gupte and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_2, 15 April 2026, Pages S60–S67, https://doi.org/10.1093/cid/ciag123
3
From Exposure to Disease: Predicting Tuberculosis Progression
从接触感染到发病：预测结核病进展
Mariana Araújo-Pereira and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_2, 15 April 2026, Pages S68–S74, https://doi.org/10.1093/cid/ciag125
4
Asymptomatic Tuberculosis Across the Disease Spectrum: A Scoping Review of Epidemiology, Diagnosis, and Public Health Implications
疾病谱中的无症状结核：一项关于流行病学、诊断和公共卫生影响的范围综述
Beatriz Barreto Duarte and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_2, 15 April 2026, Pages S75–S84, https://doi.org/10.1093/cid/ciag150
Clinical Infectious Diseases Volume 82 Issue 4
临床传染病学 82卷 4期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时光的传染病学技艺）
1
La Petite Vérole
天花
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Page i, https://doi.org/10.1093/cid/ciag118
In the Literature（文献精选）
2
In the Literature
文献精选
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages ii–v, https://doi.org/10.1093/cid/ciag013
Joint Editorial（联合社论）
3
Protocols for Randomized Controlled Trials: Advancing Transparency in Infectious Diseases
随机对照试验方案：推动传染病领域透明度提升
Jean-Jacques Parienti and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Page 557, https://doi.org/10.1093/cid/ciag198
Clinical Dilemmas in Infectious Diseases（临床传染病疑难杂症）
4
Uncertain Terrain
不确定的领域
Kap Sum Foong and Sara W Dong
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 558–561, https://doi.org/10.1093/cid/ciaf283
Voices of ID（传染病之声）
5
Lessons I Learned from Our Soldier
我从我们的士兵身上学到的经验
Mitchell J Schwaber
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 562–563, https://doi.org/10.1093/cid/ciaf433
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
6
Long-Acting Cabotegravir/Rilpivirine, Lenacapavir, and Ibalizumab Use Among Persons With HIV-1 Viremia at a Ryan White-Funded Clinic in the Urban US South
美国南部城市由瑞安·怀特资助的诊所中，HIV-1病毒血症患者使用长效卡博特韦/利匹韦林、来那卡帕韦和艾巴利珠单抗的情况
Jonathan A Colasanti and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 564–574, https://doi.org/10.1093/cid/ciaf425
7
In the Mismatch: Viral Suppression Despite Low Tenofovir-Diphosphate in Dried Blood Spots in the Multicenter AIDS Cohort Study/Women's Interagency HIV Study Combined Cohort
矛盾现象：在多中心艾滋病队列研究/妇女跨机构HIV研究联合队列中，尽管干燥血斑中磷酸替诺福韦水平低，但仍能实现病毒抑制
Sarah C Mann and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 575–582, https://doi.org/10.1093/cid/ciaf509
8
Prognostic Value of Blood Epigenetic Biomarkers of Aging in Persons With Well-Controlled HIV-1 Infection
血液衰老表观遗传生物标志物在HIV-1感染控制良好人群中的预后价值
Patricia Martínez-Martín and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 583–591, https://doi.org/10.1093/cid/ciaf537
9
HIV Resistance to Dolutegravir Varies With Coadministered Agents
HIV对多替拉韦的耐药性随联合用药的不同而有所差异
Ingrid A Beck and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 592–596, https://doi.org/10.1093/cid/ciaf481
Immunocompromised Hosts（免疫功能低下宿主）
10
Letermovir Prophylaxis Guided by Cytomegalovirus Cell-Mediated Immunity Improves the Outcomes of Allogeneic Hematopoietic Stem Cell Transplant Recipients
基于巨细胞病毒细胞介导免疫的莱特莫韦预防可改善异体基因造血干细胞移植受者的预后
Luxiang Wang and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 597–606, https://doi.org/10.1093/cid/ciaf410
11
Changing Clinical and Laboratory Characteristics of Progressive Multifocal Leukoencephalopathy: A Retrospective National Cohort Study
进行性多灶性白质脑病临床和实验室特征的变化：一项回顾性全国队列研究
Ilaria Mainardi and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 607–617, https://doi.org/10.1093/cid/ciaf501
12
Respiratory Syncytial Virus After Chimeric Antigen Receptor T-cell Therapy: Risk Factors and Outcomes in a Multicenter Retrospective Cohort
嵌合抗原受体T细胞疗法后呼吸道合胞病毒感染：一项多中心回顾性队列研究中的风险因素和预后
Maria Isabel Sotelo-Alva and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 618–621, https://doi.org/10.1093/cid/ciag052
Respiratory Infections（呼吸道感染）
13
Infectious Diseases Society of America (IDSA) Position Statement: Why IDSA Did Not Endorse the Community-Acquired Pneumonia Guidelines 2025 Update
美国传染病学会（IDSA）立场声明：为何IDSA未认可《2025年社区获得性肺炎指南》更新版
Michael Klompas and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 622–624, https://doi.org/10.1093/cid/ciaf625
14
We Dissent: Lessons From the 2025 Community-Acquired Pneumonia Guidelines
我们持不同意见：从《2025年社区获得性肺炎指南》中汲取的教训
Leila S Hojat and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 625–629, https://doi.org/10.1093/cid/ciaf626
15
Associations Between Antibiotic Use and Outcomes in Patients Hospitalized With Community-Acquired Pneumonia and Positive Respiratory Viral Assays
社区获得性肺炎且呼吸道病毒检测呈阳性住院患者抗生素使用与预后的关联
Brett Biebelberg and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 630–638, https://doi.org/10.1093/cid/ciaf687
16
Comparative Effectiveness of Azithromycin Versus Doxycycline in Hospitalized Patients With Community-Acquired Pneumonia Treated With Beta-Lactams: A Multicenter Matched Cohort Study
联合β-内酰胺类药物治疗社区获得性肺炎的住院患者中，阿奇霉素与多西环素疗效的比较：一项多中心匹配队列研究
Yewande E Odeyemi and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 639–647, https://doi.org/10.1093/cid/ciaf252
17
Target Trial Emulation of Empiric Antibiotics on Clinical Outcomes in Moderately Immunocompromised Patients Hospitalized With Pneumonia
针对中度免疫功能低下肺炎住院患者，经验性抗生素对临床预后的目标试验模拟研究
Louis Saravolatz and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 648–657, https://doi.org/10.1093/cid/ciaf344
18
Impact of Respiratory Syncytial Virus Immunization on the Rate of Pediatric Acute Otitis Media: A Time-series Analysis
呼吸道合胞病毒免疫接种对儿童急性中耳炎发生率的影响：一项时间序列分析
Inès Fafi and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 658–664, https://doi.org/10.1093/cid/ciaf564
Vaccines（疫苗）
19
LC16m8 for Pre-exposure Prophylaxis Against Mpox in a High-Risk Population: An Open-Label Randomized Trial
使用LC16m8针对高危人群进行猴痘暴露前预防：一项开放标签随机试验
Nobumasa Okumura and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 665–672, https://doi.org/10.1093/cid/ciaf074
20
Immunogenicity and Safety of 2 Versus 3 Doses of 9-Valent Vaccine Against Human Papillomavirus in Women With Human Immunodeficiency Virus: The Papillon Randomized Trial
在感染人类免疫缺陷病毒的女性中，接种2剂与3剂九价人乳头瘤病毒疫苗的免疫原性和安全性：Papillon随机试验
Deborah Konopnicki and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 673–681, https://doi.org/10.1093/cid/ciaf241
21
Screening and Vaccination Rates for Tetanus, Hepatitis A, and Hepatitis B Among Individuals With Substance Use Disorders Hospitalized in an Integrated US Health System
在美国综合医疗机构中住院的成瘾性患者的破伤风、甲型肝炎和乙型肝炎筛查及接种率
Jennifer H Ku and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 682–688, https://doi.org/10.1093/cid/ciaf251
22
Atrial Fibrillation After Respiratory Syncytial Virus Vaccination Among Older Adults
老年人接种呼吸道合胞病毒疫苗后发生心房颤动的情况
Morgan Birabaharan and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 689–691, https://doi.org/10.1093/cid/ciae649
23
Approaches to Comparing Influenza Vaccine Effectiveness to Guide Potential Preferential Product Recommendations
比较流感疫苗有效性的方法，以指导可能的优先产品推荐
Edward A Belongia and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 692–697, https://doi.org/10.1093/cid/ciaf563
Viral Infections（病毒性感染）
24
Clinical Features and Outcomes of Human Herpesvirus-6 DNAemia in Critically Ill Patients: A Retrospective Multicenter Analysis
危重患者人类疱疹病毒6型DNA血症的临床特征和预后：一项回顾性多中心分析
Margot Combet and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 698–708, https://doi.org/10.1093/cid/ciaf199
25
Kaposi Sarcoma–Associated Herpesvirus Risk and Disease in Kidney Donors and Transplant Recipients With HIV in the United States
美国HIV感染肾捐赠者和移植受者中卡波西肉瘤相关疱疹病毒的风险和疾病
Puja H Nambiar and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 709–719, https://doi.org/10.1093/cid/ciaf229
26
Clinical Outcomes of Mpox Disease in Patients Treated With Tecovirimat
接受特考韦瑞治疗的猴痘病患者的临床预后
Ciarra Leocadio and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 720–726, https://doi.org/10.1093/cid/ciaf520
27
Effective Antivirals in Pandemic Preparedness: Past Mistakes, Future Needs
大流行防范中的有效抗病毒药物：过去的错误，未来的需求
Antonios-Periklis Panagiotopoulos and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 727–733, https://doi.org/10.1093/cid/ciaf648
Photo Quizzes（影像问答）
28
From Soil to Skin: An Unexpected Cause of Necrotizing Cellulitis
从土壤到皮肤：坏死性蜂窝织炎的意外病因
Erica Peak and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 734–737, https://doi.org/10.1093/cid/ciaf555
29
A 67-year-Old Immunocompromised Male Presenting With Right Upper-Quadrant Abdominal Pain and Hepatic Lesions
一例67岁免疫功能低下男性，出现右上腹疼痛和肝脏病变
Sara Yousef Zadeh Shoushtari and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 738–741, https://doi.org/10.1093/cid/ciaf729
Bacterial Infections（细菌性感染）
30
Patient-reported Perceptions, Experiences, and Preferences Around Intravenous and Oral Antibiotics for the Treatment of Staphylococcus aureus Bacteremia: A Descriptive Qualitative Study
金黄色葡萄球菌菌血症患者对静脉和口服抗生素治疗的自我报告认知、体验和偏好：一项描述性质性研究
Genevieve Walls and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e635–e642, https://doi.org/10.1093/cid/ciaf522
31
Reproducible Identification of Staphylococcus aureus Bacteremia Clinical Subphenotypes
金黄色葡萄球菌菌血症临床亚型的可重复性识别
Maaike C Swets and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e643–e651, https://doi.org/10.1093/cid/ciaf655
32
Disease Trends and Mortality From Invasive Pneumococcal Disease: A Long-Term Population-Based Study
侵袭性肺炎球菌病的疾病趋势和死亡率：一项长期人群基础研究
Hörður Tryggvi Bragason and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e652–e661, https://doi.org/10.1093/cid/ciaf670
33
When and How to Use Subcutaneous Antibiotics
皮下注射抗生素的使用时机和方法
Stefano Di Bella and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e662–e673, https://doi.org/10.1093/cid/ciaf691
Clinical Trials（临床实验）
34
Using the Comparing Oral versus Parenteral Antimicrobial Therapy (COPAT) Clinical Trial to Influence Institutional Practice Transformation Towards Earlier Transition to Oral Antibiotics
利用口服与肠外抗菌治疗比较（COPAT）临床实验推动机构实践转型，以更早地过渡到口服抗生素治疗
Joy J Juskowich and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e674–e681, https://doi.org/10.1093/cid/ciaf707
35
The Fate of Oral Meds
口服药物的命运
Monica V Mahoney
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e682–e683, https://doi.org/10.1093/cid/ciaf708
36
Early Symptom Response in Patients With Uncomplicated Urinary Tract Infection Treated With Gepotidacin or Nitrofurantoin: Pooled Analysis From Two Pivotal Phase 3 Studies
接受吉泊西汀或呋喃妥因治疗的无并发症尿路感染患者的早期症状反应：两项关键性3期研究的汇总分析
Amanda J Sheets and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e684–e692, https://doi.org/10.1093/cid/ciaf722
37
Regional Variations of Rates and Determinants of Drug Resistance Mutations in People Failing First-line Therapy for HIV-1: A Substudy from the D2EFT Phase 3b/4 Clinical Trial
HIV-1一线治疗失败人群中耐药突变发生率和决定因素的区域差异：D2EFT 3b/4期临床试验的子研究
Billal Musah Obeng and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e693–e704, https://doi.org/10.1093/cid/ciaf739
38
What's Hot This Year in ID Clinical Science 2025
2025年传染病临床学科领域的年度热点
Jeffrey A Freiberg and Patty W Wright
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e705–e709, https://doi.org/10.1093/cid/ciaf740
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
39
Impact of Vaginal Estradiol on the Genitourinary Syndrome of Menopause, Vaginal Microbiome and Mucosal Immune Mediators in Women With HIV
阴道雌二醇对HIV感染女性绝经生殖泌尿综合征、阴道微生物群和黏膜免疫介质的影响
Kerry Murphy and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e710–e719, https://doi.org/10.1093/cid/ciaf669
40
Pharmacokinetics of Twice-daily Tenofovir Alafenamide in Adults With HIV-associated Tuberculosis on Bictegravir/Emtricitabine/Tenofovir Alafenamide and Rifampicin
在接受比克替拉韦/恩曲他滨/丙酚替诺福韦和利福平治疗的HIV相关结核病成人患者中，每日两次丙酚替诺福韦的药代动力学
Emmanuella Chinonso Osuala and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e720–e727, https://doi.org/10.1093/cid/ciaf732
41
Integrating HIV and Stimulant-Use Disorder Treatment: A Pilot Implementation Effectiveness Trial of Contingency Management in HIV Care
整合HIV和兴奋剂使用障碍治疗：在HIV护理中开展应急管理试点实施效果试验
Ayesha Appa and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e728–e734, https://doi.org/10.1093/cid/ciag006
42
Hepatitis B Reactivation in a US Cohort of People With HIV and Hepatitis B Core Antibody After Switch to Antiretroviral Therapy Without Hepatitis B Activity
美国HIV和乙型肝炎核心抗体阳性人群在转换为无抗乙肝病毒活性的抗逆转录病毒治疗后乙型肝炎复发的队列研究
Rachel V Denyer and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e735–e742, https://doi.org/10.1093/cid/ciag001
43
Hepatitis B Virus Reactivation in People With HIV After Treatment With Non-hepatitis B Virus-Active Antiretroviral Therapy
接受无抗乙肝病毒活性的抗逆转录病毒治疗的HIV感染者乙型肝炎病毒复发情况
Amir M Mohareb and Anders Boyd
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e743–e745, https://doi.org/10.1093/cid/ciag002
44
The Potential Effect of Ending Centers for Disease Control and Prevention Funding for HIV Tests: A Modeling Study in 18 States
终止美国疾病控制与预防中心对HIV检测资助的潜在影响：对18个州的建模研究
Ruchita Balasubramanian and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e746–e754, https://doi.org/10.1093/cid/ciag038
45
Cutting Federal Funds for HIV Testing Means Not Ending the HIV Epidemic
削减HIV检测的联邦资金意味着无法终结HIV流行
Sarah E Scott and Joshua A Barocas
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e755–e756, https://doi.org/10.1093/cid/ciag039
Infection Control and Hospital Epidemiology（感染控制与医院流行病学）
46
Cluster-Randomized Controlled Trial of Enhanced Carbapenem-Resistant Enterobacterales Prevention Program in General Medicine Wards, Siriraj Hospital
西拉查医院普通内科病房强化碳青霉烯类耐药肠杆菌科细菌预防计划的整群随机对照试验
Apiradee Taweesuk and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e757–e764, https://doi.org/10.1093/cid/ciaf523
47
Risk Factors Associated With Progression to Clinical Candida auris Infection Among Adults With Previous Colonization—Florida, 2019–2023
2019-2023年佛罗里达州既往定植的成人进展为临床耳念珠菌感染的相关风险因素
Katharine E Saunders and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e765–e772, https://doi.org/10.1093/cid/ciaf551
48
Using Generative Artificial Intelligence to Identify Central Line–associated Bloodstream Infections
利用生成式人工智能识别中心静脉导管相关血流感染
Daniel J Morgan and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e773–e780, https://doi.org/10.1093/cid/ciaf636
49
Infection Control in Carceral Facilities
监狱设施中的感染控制
Amadin A Olotu and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e781–e790, https://doi.org/10.1093/cid/ciaf479
50
Infection Prevention and Control in Carceral Settings
监狱环境中的感染预防与控制
April N McDougal and Lara B Strick
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e791–e793, https://doi.org/10.1093/cid/ciaf480
51
Impact of Discontinuation of Contact Precautions on Healthcare-associated Extended Spectrum β-Lactamase-Producing Escherichia coli in a Large Tertiary Care Hospital: An Interrupted Time-series Analysis
一家大型三级医院停止接触预防措施对医院获得性产超广谱β-内酰胺酶大肠埃希菌的影响：一项中断时间序列分析
Stefano Musumeci and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e794–e798, https://doi.org/10.1093/cid/ciaf594
Respiratory Infections（呼吸道感染）
52
Estimating Risk of Guillain-Barré Syndrome in US Medicare-enrolled Older Adults Following Medically Attended Respiratory Syncytial Virus Disease: A Self-controlled Case Series Analysis
美国医疗保险参保老年人因需就医的呼吸道合胞病毒疾病后患吉兰-巴雷综合征的风险评估：一项自我对照病例系列分析
Caihua Liang and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e799–e806, https://doi.org/10.1093/cid/ciaf621
53
Independent Testing to Accelerate the Development of Lateral Flow Assays for Influenza A, Influenza B and SARS-COV-2
独立检测以加速甲型流感、乙型流感和严重急性呼吸系统综合征冠状病毒2型侧流层析检测法的开发
Anuradha Rao and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e807–e815, https://doi.org/10.1093/cid/ciaf660
54
Diagnostic Yield of Tongue Swab- Compared to Sputum-Based Molecular Testing for Tuberculosis in Four High-Burden Countries
在四个高负担国家，与痰液分子检测相比，舌拭子检测对结核病的诊断效果
Caitlin A Moe and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e816–e823, https://doi.org/10.1093/cid/ciag077
55
Are We Ready for the Gift Tongues Can Give to Tuberculosis?
我们准备好接受舌头为结核病诊断带来的“馈赠”了吗？
Michael R Barer
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e824–e825, https://doi.org/10.1093/cid/ciag078
Sexually Transmitted Infections（性传播感染）
56
Evaluating the Impact of Implementing and Scaling-Up the Use of Syphilis Rapid/Point-of-Care Tests: An Interrupted Time Series Analysis of New Syphilis Positivity Rates in Alberta, Canada
评估实施和扩大梅毒快速/即时检测使用的影响：加拿大阿尔伯塔省新发梅毒阳性率的中断时间序列分析
L Alexa Thompson and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e826–e835, https://doi.org/10.1093/cid/ciaf651
57
Human Papillomavirus-Related Anal Precancerous Lesions in Men Who Have Sex With Men: A Comparative Study of Pre-exposure Prophylaxis Users and HIV-Positive Individuals
男男性行为者中与人乳头瘤病毒相关的肛门癌前病变：暴露前预防用药者与HIV阳性者的对比研究
Magali Surmont and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e836–e842, https://doi.org/10.1093/cid/ciaf724
58
Is 3 Really What We Need? Relative Effectiveness of Benzathine Penicillin G and Doxycycline Treatment Regimens for Late or Unknown Duration Syphilis in 6 US Jurisdictions, 2016–2021
我们需要“3”吗？2016-2021年美国6个司法管辖区晚期或病程不明梅毒患者使用苄星青霉素G和多西环素治疗方案的相对疗效
River A Pugsley and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e843–e851, https://doi.org/10.1093/cid/ciag099
59
Strong Real-World Evidence That a Single Dose of Benzathine Penicillin G or a 28-Day Course of Oral Doxycycline Is Not Inferior to 3 Doses of Benzathine Penicillin G for the Treatment of Late Latent or Unknown Duration Syphilis
强力现实证据表明，单剂苄星青霉素G或28天口服多西环素治疗晚期潜伏梅毒或病程不明梅毒的疗效并不逊于3剂苄星青霉素G
Noah Kojima and Jeffrey D Klausner
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e852–e854, https://doi.org/10.1093/cid/ciag101
Vaccines（疫苗）
60
Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345, an mRNA Vaccine Against Respiratory Syncytial Virus, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years
对≥50岁成年人，在初次接种12个月后再次接种针对呼吸道合胞病毒的mRNA疫苗mRNA-1345的安全性、耐受性和免疫原性
Jaya Goswami and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e855–e862, https://doi.org/10.1093/cid/ciaf515
61
Analysis of Antibody Markers as Immune Correlates of Risk of Severe COVID-19 in the PREVENT-19 Efficacy Trial of the NVX-CoV2373 Recombinant Protein Vaccine
在NVX-CoV2373重组蛋白疫苗PREVENT-19有效性试验中，抗体标志物作为严重新型冠状病毒肺炎风险免疫相关因素的分析
Youyi Fong and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e863–e874, https://doi.org/10.1093/cid/ciaf558
62
Is It Time to Reassess the Target Age of Human Papillomavirus Vaccination Globally?
现在是时候重新评估全球人乳头瘤病毒疫苗接种的目标年龄了吗？
Edie Brassington and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e875–e883, https://doi.org/10.1093/cid/ciaf679
63
Preschool or Infant Human Papillomavirus Immunization?
学龄前还是婴儿期接种人乳头瘤病毒疫苗？
Mark A Kane and Eduardo L Franco
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e884–e886, https://doi.org/10.1093/cid/ciaf678
Correspondence（读者来信）
64
Caution in Interpreting Equivalence From Nonsignificant Findings in Antiretroviral Switch Studies
谨慎解读抗逆转录病毒药物转换研究中非显著性结果得出的等效性结论
Esteban Martinez
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e887–e888, https://doi.org/10.1093/cid/ciaf675
65
Clarifying INSTINCT: Switching From Dolutegravir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Shows Comparable Inflammatory and Weight Outcomes
阐明INSTINCT研究：从多替拉韦/拉米夫定转换为比克替拉韦/恩曲他滨/丙酚替诺福韦显示出相似的炎症和体重结果
Sergio Serrano-Villar and Santiago Moreno
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e888–e889, https://doi.org/10.1093/cid/ciaf676
66
Can Doxycycline Prophylaxis Indirectly Reduce Congenital Syphilis?
多西环素预防能否间接降低先天性梅毒的发生率？
Kalpana Gopalkrishnan and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e889–e891, https://doi.org/10.1093/cid/ciaf694
67
The Urgency of Now: Congenital Syphilis in the Doxycycline Post-exposure Prophylaxis Era
迫在眉睫：多西环素暴露后预防时代的先天性梅毒问题
Matthew A Spinelli and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Page e891, https://doi.org/10.1093/cid/ciaf695
68
Routine HIV RNA Testing During Injectable Cabotegravir and Oral Preexposure Prophylaxis Use
注射用卡博特韦和口服暴露前预防用药期间进行常规HIV RNA检测
Angelo Roberto Raccagni and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e891–e892, https://doi.org/10.1093/cid/ciaf702
69
Simplifying Testing for Human Immunodeficiency Virus During Pre-exposure Prophylaxis Monitoring
简化暴露前预防监测期间的人类免疫缺陷病毒检测
Weiming Zhu and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e892–e893, https://doi.org/10.1093/cid/ciaf703
70
Methodological Considerations in Evaluating Oral Antivirals for B-Cell-Depleted Patients
评估B细胞耗竭患者口服抗病毒药物的方法学考量
Wenjing Chen and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e893–e894, https://doi.org/10.1093/cid/ciaf717
71
Target Trial Emulation of Oral Antivirals for B-Cell-Depleted COVID-19 Patients—Reply to Chen et al
B细胞耗竭型新型冠状病毒肺炎患者口服抗病毒药物的靶试验模拟——回复Chen等人的评论
Xiaofeng F Wang and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e894–e895, https://doi.org/10.1093/cid/ciaf718
72
Misleading Conclusion That Is Not in Accordance With the Results of the Reported Randomized, Controlled Trial
与所报告的随机对照试验结果不符的误导性结论
Charlotte Strøm
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e895–e896, https://doi.org/10.1093/cid/ciaf659
73
Vaccine Policy Pendulum: A Lesson From Japan
疫苗政策摇摆不定：日本的教训
Masaki Machida and Wakaba Fukushima
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e896–e897, https://doi.org/10.1093/cid/ciaf689
74
Herpes Zoster, Vaccine, and Stroke Risk
带状疱疹、疫苗与中风风险
Shih-Wei Lai and Sheng-Chun Chiu
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e897–e898, https://doi.org/10.1093/cid/ciaf725
100 项与 替诺福韦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 病毒感染 | 中国 | 2008-06-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 乙型肝炎病毒相关肝细胞癌 | 临床3期 | 中国台湾 | 2012-09-01 | |
| 慢性乙型肝炎 | 临床3期 | 中国台湾 | 2012-09-01 | |
| 单纯疱疹 | 临床3期 | 南非 | 2011-10-01 | |
| HIV感染 | 临床3期 | 比利时 | 2002-07-16 | |
| HIV感染 | 临床3期 | 加拿大 | 2002-07-16 | |
| HIV感染 | 临床3期 | 法国 | 2002-07-16 | |
| HIV感染 | 临床3期 | 德国 | 2002-07-16 | |
| HIV感染 | 临床3期 | 意大利 | 2002-07-16 | |
| HIV感染 | 临床3期 | 葡萄牙 | 2002-07-16 | |
| HIV感染 | 临床3期 | 西班牙 | 2002-07-16 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床1期 | 49 | Tenofovir+TFV (Tenofovir (TFV) Intravaginal Ring (IVR)) | 襯積艱築蓋鹽獵積積壓(淵壓壓築糧艱範選網膚) = 壓範鏇選獵餘鹹選獵繭 淵憲觸觸衊觸鹽鏇選窪 (製鹽鏇網憲遞夢膚鏇範, 131.2) 更多 | - | 2025-11-13 | ||
Placebo IVR (Placebo IVR) | 膚壓選觸積艱鏇願衊獵 = 壓膚襯顧網餘繭淵齋鹽 構壓鬱構築積餘淵窪製 (衊鹹範壓壓醖齋繭廠網, 襯網範憲齋齋膚糧鏇顧 ~ 積憲衊齋鬱繭鏇鏇淵齋) 更多 | ||||||
临床1期 | HIV感染 HIV-negative | 8 | 構網蓋窪網範糧範襯糧(鏇鏇鬱齋窪鹹選淵蓋鏇) = Five mild to moderate AEs (e.g., nausea, hyperglycemia) were reported, none related to the product 夢鑰蓋鏇範顧獵廠壓齋 (簾餘鏇壓製艱醖獵夢鑰 ) | 积极 | 2025-06-28 | ||
N/A | - | PrEP (Usual clinic flow) | 鹽夢鹹夢獵鬱襯糧夢餘(願蓋鏇鑰網鏇餘鏇積鬱) = 積餘糧糧鹽鑰蓋積積衊 齋鑰艱醖築鏇鏇膚鬱夢 (築壓廠襯窪遞壓壓鹹餘 ) 更多 | - | 2024-03-01 | ||
临床1期 | HIV感染 TFV concentrations | 49 | 餘淵艱艱繭襯衊襯遞醖(範淵鑰廠壓膚鬱構鹽衊) = 糧蓋願襯獵鹽鏇願壓糧 鬱範願鏇壓遞鹽範壓廠 (簾顧襯積壓顧選襯壓餘 ) 更多 | 积极 | 2024-03-01 | ||
Placebo Vaginal Ring | 餘淵艱艱繭襯衊襯遞醖(範淵鑰廠壓膚鬱構鹽衊) = 範夢築觸艱壓壓醖膚鹹 鬱範願鏇壓遞鹽範壓廠 (簾顧襯積壓顧選襯壓餘 ) 更多 | ||||||
临床1期 | 8 | 憲獵範膚壓膚衊製壓鹹(糧醖鏇繭遞窪膚鑰憲願) = 蓋繭積鹽積積窪鏇襯鹽 構鹽糧鏇製齋襯觸製繭 (衊積積積艱鏇蓋膚蓋壓, 襯襯膚夢築構憲顧觸鹹 ~ 鬱觸廠衊簾築願窪夢積) 更多 | - | 2023-10-30 | |||
临床1期 | 10 | 廠獵廠蓋憲齋構鏇齋夢(糧選艱蓋廠鬱構醖餘簾) = 廠網餘願衊積鹽遞築顧 觸齋觸簾憲鏇膚鬱鑰構 (鏇襯獵獵醖簾憲餘夢襯, 819.0428) 更多 | - | 2023-04-12 | |||
N/A | 201 | Tenofovir disoproxil fumarate (TDF) + Peginterferon (PegIFN) alfa-2a | 製淵齋襯鹽艱鹽膚構構(鬱夢選範築網鏇積艱壓) = 壓壓鬱繭齋願製窪窪顧 鹽淵鹹觸遞齋齋遞鏇鑰 (衊蓋餘餘範鏇醖積蓋獵 ) | - | 2023-01-05 | ||
Tenofovir disoproxil fumarate (TDF) alone | 製淵齋襯鹽艱鹽膚構構(鬱夢選範築網鏇積艱壓) = 衊鬱鹹鏇繭簾觸觸艱選 鹽淵鹹觸遞齋齋遞鏇鑰 (衊蓋餘餘範鏇醖積蓋獵 ) | ||||||
临床2期 | HIV | hepatitis B surface antigen | HSV-2 | 27 | Tenofovir/Levonorgestrel (TFV/LNG) Intravaginal Ring | 壓觸簾鑰糧願鑰簾製窪(製鏇憲衊衊鑰艱窪獵積) = 窪齋鏇願廠鹽醖憲鹽壓 膚膚鬱窪鑰醖鑰糧醖製 (鬱網廠糧構夢遞鑰獵網 ) 更多 | - | 2023-01-01 | |
壓觸簾鑰糧願鑰簾製窪(製鏇憲衊衊鑰艱窪獵積) = 壓窪簾糧夢鬱製鏇壓淵 膚膚鬱窪鑰醖鑰糧醖製 (鬱網廠糧構夢遞鑰獵網 ) 更多 | |||||||
临床3期 | 201 | (Tenofovir) | 淵鏇繭衊積築願憲膚廠 = 窪範衊鏇醖壓選糧鬱蓋 鹽衊鹹衊夢醖鹹選衊繭 (襯醖顧廠選構憲憲艱醖, 膚觸艱遞衊積鏇構積鹹 ~ 鏇繭範鬱網選積憲選襯) 更多 | - | 2022-10-12 | ||
淵鏇繭衊積築願憲膚廠 = 鑰夢鏇鏇餘醖願簾憲醖 鹽衊鹹衊夢醖鹹選衊繭 (襯醖顧廠選構憲憲艱醖, 獵繭製顧鹹網觸淵願淵 ~ 窪鬱艱築製遞艱壓糧廠) 更多 | |||||||
Pubmed 人工标引  | 临床4期 | 229 | 網選顧壓憲壓憲糧網積(築鹽艱範襯壓餘獵製網) = 389 AEs were reported from 58% of patients. Of these, 61 were related to study treatment. 淵繭醖選艱淵選壓壓膚 (簾窪窪憲繭築構積簾艱 ) 更多 | 积极 | 2022-08-10 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用